BioMedLib Search Engine [ goto HOMEPAGE ]

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Splenic diffuse red pulp small B-cell lymphoma: revision of a series of cases reveals characteristic clinico-pathological features.

BACKGROUND: Splenic diffuse red pulp small B-cell lymphoma is an uncommon B-cell lymphoma, now recognized as a provisional entity in the 2008 update of the WHO Classification.

DESIGN AND METHODS: We have retrospectively analyzed the disease features in a highly selected series of 17 patients diagnosed as splenic diffuse red pulp small B-cell lymphoma.

Clinical manifestations were mainly derived from splenomegaly.

All cases showed a purely diffuse pattern of splenic infiltration by monomorphous small cells with small round nuclei and pale cytoplasm.

Peripheral blood cells were small to medium-sized, with clumped chromatin and round nuclear outline and villous cytoplasm.

Neoplastic cells had a CD20(+), CD23(-), bcl6(-), Annexin A1- phenotype, with frequent expression of DBA44+ (15/17) and IgG (10/15).

FCM data had a B-cell phenotype (CD19(+), CD20(+), CD22(+)) with FMC7 (10/11) and CD11c (5/8) expression.

CONCLUSIONS: Our data suggest that splenic diffuse red pulp small B-cell lymphoma is a distinct entity with morphological and immunophenotypical features that differ from those of other splenic lymphomas.

[MeSH-major] Lymphoma, B-Cell / pathology. Splenic Neoplasms / pathology

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Leuk Res. 1999 Nov;23(11):1041-5 [10576509.001]

[Cites] Haematologica. 2008 May;93(5):670-9 [18367492.001]

[Cites] Blood. 2002 Feb 15;99(4):1299-304 [11830479.001]

[Cites] Histopathology. 2002 Jan;40(1):22-30 [11903595.001]

[Cites] Blood. 2003 Apr 1;101(7):2464-72 [12446449.001]

[Cites] Best Pract Res Clin Haematol. 2003 Mar;16(1):41-56 [12670464.001]

[Cites] Lancet. 2004 Jun 5;363(9424):1869-70 [15183626.001]

[Cites] Leukemia. 1987 Apr;1(4):294-8 [3499540.001]

[Cites] Am J Surg Pathol. 1996 Feb;20(2):211-23 [8554111.001]

[Cites] Histopathology. 1996 Dec;29(6):571-5 [8971565.001]

[Cites] Semin Hematol. 1999 Apr;36(2):148-54 [10319383.001]

[Cites] Am J Pathol. 1999 May;154(5):1583-9 [10329610.001]

[Cites] Am J Surg Pathol. 2007 Mar;31(3):438-46 [17325486.001]

[Cites] Blood. 2008 Feb 15;111(4):2253-60 [18042795.001]

[Cites] Leukemia. 2008 Mar;22(3):487-95 [18094718.001]

[Cites] Blood. 2001 Jun 1;97(11):3552-8 [11369650.001]

(PMID = 20220064.001).

[ISSN] 1592-8721

[Journal-full-title] Haematologica

[ISO-abbreviation] Haematologica

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Italy

[Other-IDs] NLM/ PMC2895036

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Three-dimensional culturing of the Hodgkin lymphoma cell-line L1236 induces a HL tissue-like gene expression pattern.

To overcome some limitations of in vitro established cell-line tumor models for Hodgkin lymphoma (HL), we explored whether culturing in a three-dimensional (3D) matrix could improve the quality of the model.

The gene expression profile of the 3D-cultured HL derived cell-line L1236 was compared with that of suspension-cultured (2D) L1236, as well as to the gene expression profile found in HL tumor samples.

To validate our results we also included a gene expression data set of laser captured Hodgkin-Reed - Sternberg (H-RS) cells.

We found that the 3D culture affected gene expression of a HL derived cell-line inducing a more tumor-related expression profile.

3D culture affected the expression of 500 genes in L1236, upregulating genes involved in immune response and apoptosis and downregulating genes involved in cell division.

[MeSH-major] Cell Culture Techniques / methods. Gene Expression Profiling / methods. Gene Expression Regulation, Neoplastic. Hodgkin Disease / pathology. Reed-Sternberg Cells / pathology

[MeSH-minor] Apoptosis. Biopsy. Cell Line, Tumor. Computational Biology. Humans. Lymph Nodes / pathology. Models, Genetic. Oligonucleotide Array Sequence Analysis. Peptides / chemistry. RNA, Neoplasm / metabolism

Genetic Alliance. consumer health - Hodgkin lymphoma.

MedlinePlus Health Information. consumer health - Hodgkin Disease.

COS Scholar Universe. author profiles.

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17917972.001).

[ISSN] 1042-8194

[Journal-full-title] Leukemia & lymphoma

[ISO-abbreviation] Leuk. Lymphoma

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Peptides; 0 / RNA, Neoplasm

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [A case of natural killer cell lymphoma with high adenosine deaminase level in pleural effusion].

We finally diagnosed the case as natural killer (NK) cell lymphoma from CT-guided needle biopsy just before death, and necropsy.

In this case, the high level of ADA in the pleural effusion suggested lymphoma.

[MeSH-major] Adenosine Deaminase / metabolism. Killer Cells, Natural. Lymphoma, Non-Hodgkin / diagnosis. Pleural Effusion, Malignant / diagnosis

[MeSH-minor] Diagnosis, Differential. Humans. Male. Middle Aged. Pleura / pathology

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15997786.001).

[ISSN] 1343-3490

[Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society

[ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi

[Language] jpn

[Publication-type] Case Reports; English Abstract; Journal Article

[Publication-country] Japan

[Chemical-registry-number] EC 3.5.4.4 / Adenosine Deaminase

   

Advertisement

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Influence of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone on serologic parameters and clinical course in lymphoma patients with autoimmune diseases.

BACKGROUND: As patients with B-cell lymphomas suffering from an underlying autoimmune condition undergoing therapy with the CD20 antibody rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) offer the unique possibility of monitoring effects of therapy on various rheumatologic parameters, we have evaluated serologic autoimmune markers and the clinical outcome of patients with autoimmune diseases (ADs) who received lymphoma treatment with R-CHOP during the course of their disease.

PATIENTS AND METHODS: We have retrospectively analysed 13 patients with non-Hodgkin's lymphoma who concurrently suffered from ADs and were treated with the R-CHOP regimen.

Ten (77%) patients showed clinical improvement of their autoimmune symptoms, two (15%) reported no difference and one (7%) patient with rheumatoid arthritis-related worsening symptoms during therapy with R-CHOP.

In terms of lymphoma response, 11 patients achieved a complete remission and two a partial remission.

CONCLUSIONS: This analysis indicates that R-CHOP given for lymphoma treatment is also effective for therapy of concurrent rheumatoid diseases.

Both rheumatoid parameters as well as clinical symptoms showed a significant decrease during treatment with this immunochemotherapy.

Genetic Alliance. consumer health - Autoimmune Diseases.

MedlinePlus Health Information. consumer health - Autoimmune Diseases.

Hazardous Substances Data Bank. RITUXIMAB .

Hazardous Substances Data Bank. DOXORUBICIN .

Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

Hazardous Substances Data Bank. PREDNISONE .

Hazardous Substances Data Bank. VINCRISTINE .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[CommentIn] Ann Oncol. 2007 Apr;18(4):615-8 [17355949.001]

(PMID = 17218490.001).

[ISSN] 0923-7534

[Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology

[ISO-abbreviation] Ann. Oncol.

[Language] ENG

[Publication-type] Journal Article

[Publication-country] England

[Chemical-registry-number] 0 / Antibodies, Antinuclear; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9009-79-4 / Rheumatoid Factor; VB0R961HZT / Prednisone

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Diethyl maleate-induced oxidative stress leads to testicular germ cell apoptosis involving Bax and Bcl-2.

Testicular germ cell apoptosis is normally a continuous process throughout life.

However, massive testicular germ cell loss is known to result from a wide variety of cellular stresses including toxicant exposure.

Thus, the present study was aimed to investigate the mechanisms of germ cell loss under stress conditions following diethyl maleate (DEM) exposure.

The germ cell apoptosis was found to be increased as assessed by terminal deoxynucleotidyl transferase (TdT)-mediated deoxy-UTP biotin nick end labeling (TUNEL) staining, evaluation of histoarchitechture of testis, and germ cell numbers.

It was found that the germ cell number was significantly reduced in DEM-treated sections.

RT-PCR was carried out to assess Bax/Bcl-2 mRNA expression levels.

Immunohistochemistry of Bax and Bcl-2 revealed Bax activation.

The prevalence and cellular localization of the above markers in testicular tissues of DEM-treated animals suggest the possible involvement of Bax/Bcl-2 in the male germ cell apoptosis.

[MeSH-major] Apoptosis / drug effects. Maleates / toxicity. Oxidative Stress / drug effects. Spermatozoa / cytology. Spermatozoa / drug effects. Testis / cytology. bcl-2-Associated X Protein / metabolism

[MeSH-minor] Animals. Cell Shape / drug effects. Gene Expression Regulation / drug effects. Immunohistochemistry. In Situ Nick-End Labeling. Male. Mice. Mice, Inbred BALB C. RNA, Messenger / genetics. RNA, Messenger / metabolism

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] (c) 2008 Wiley Periodicals, Inc.

(PMID = 19110998.001).

[ISSN] 1099-0461

[Journal-full-title] Journal of biochemical and molecular toxicology

[ISO-abbreviation] J. Biochem. Mol. Toxicol.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Maleates; 0 / RNA, Messenger; 0 / bcl-2-Associated X Protein; G81WQB56OL / diethyl maleate

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Dissociation of caspase-mediated events and programmed cell death induced via HLA-DR in follicular lymphoma.

Human leukocyte antigens (HLA) class II antigen-mediated apoptosis has been documented in antigen-presenting cells and B lymphoproliferations.

Characteristics of the apoptosis include rapidity and selectivity for mature cells.

Follicular lymphomas are particularly refractory to apoptosis.

The B-cell lymphoma Ramos shares characteristics of this subgroup and is insensitive to apoptosis via simple HLA-DR engagement.

However, inhibition of caspase activation simply delayed the apoptotic phenotype but neither protected against cell death nor prevented mitochondrial injury.

Finally, blockade of caspase activation in parallel with HLA-DR mAb stimulation could provide a potent autovaccination stimulus by leading to necrotic death of B-cell lymphomas.

[MeSH-major] Apoptosis. Caspase Inhibitors. Caspases / metabolism. HLA-DR Antigens / physiology. Lymphoma, Follicular / genetics. Lymphoma, Follicular / pathology

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16301998.001).

[ISSN] 0950-9232

[Journal-full-title] Oncogene

[ISO-abbreviation] Oncogene

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Caspase Inhibitors; 0 / HLA-DR Antigens; EC 3.4.22.- / Caspases

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Direct antilymphoma activity of novel, first-generation "antibody mimics" that bind HLA-DR10-positive non-Hodgkin's lymphoma cells.

A first-generation series of novel small molecules, collectively known as selective high-affinity ligands (SHALs), were designed and synthesized to mimic the binding of Lym-1, a monoclonal antibody (mAb) shown to be an effective cytotoxic and radionuclide carrier molecule for targeting non-Hodgkin's lymphoma (NHL).

Micromolar concentrations of all three SHALs showed binding to Raji, an HLA-DR10-positive human malignant B-cell line but no binding to CEM or Jurkat's, HLA-DR10-negative malignant T-cell lines.

Additionally, the Raji cell membrane distributions of all three SHALs and of Lym-1 were remarkably similar.

Unlike Lym-1, which causes substantial growth inhibition and cell death in NHL cell lines, these SHALs had no direct antilymphoma activity.

In summary, three first-generation SHALs lacked direct antilymphoma activity, although they had selective NHL B-cell binding like Lym-1 mAb.

Because of their small size, these SHALs have potential as radionuclide carrier substitutes for Lym-1 mAb to target the HLA-DR10 NHL-related cell-surface protein.

[MeSH-major] Antibodies, Monoclonal / chemistry. Antineoplastic Agents / chemistry. Antineoplastic Agents / pharmacology. Biomimetic Materials / chemistry. Biomimetic Materials / pharmacology. HLA-DR Antigens / metabolism. Lymphoma, Non-Hodgkin / metabolism

[MeSH-minor] Antibodies, Monoclonal, Murine-Derived. Cell Line, Tumor. Cell Survival / drug effects. Enzyme-Linked Immunosorbent Assay. HLA-DR Serological Subtypes. Humans. Ligands. Streptavidin / metabolism

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17257080.001).

[ISSN] 1084-9785

[Journal-full-title] Cancer biotherapy & radiopharmaceuticals

[ISO-abbreviation] Cancer Biother. Radiopharm.

[Language] eng

[Grant] United States / NCI NIH HHS / CA / CA 47829

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.

[Publication-country] United States

[Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / HLA-DR Antigens; 0 / HLA-DR Serological Subtypes; 0 / HLA-DR10 antigen; 0 / Ligands; 0 / Lym-1 monoclonal antibody; 9013-20-1 / Streptavidin

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Immunoreactivity of p53, Mdm2, p21(WAF1/CIP1) Bcl-2, and Bax in soft tissue sarcomas: correlation with histologic grade.

Tumor growth depends on 2 distinctive pathways: cell proliferation and apoptosis.

The p53 pathway is an important regulator of the cell cycle as it triggers growth arrest or leads to apoptosis in response to cellular stress and therefore is commonly targeted during tumorigenesis.

Apoptosis is also controlled by the Bcl-2 family, which includes proapoptotic and antiapoptotic proteins.

Immunohistochemical stains for p21(WAF1/CIP1), p53, Mdm2, Bcl-2, and Bax proteins were carried out on tissue microarrays.

Expression of Bax protein was a common finding in soft tissue sarcoma cases.

Bcl-2 was identified in 59 tumors (38.8%) and was more prevalent in high-grade sarcomas (low grade, 25.9%; intermediate grade, 32.5%; high grade, 55.2%).

The expression of p53, p21(WAF1/CIP1), and Bcl-2 is closely associated with the histologic grade of the tumor, and therefore these proteins may be used as prognostic markers.

MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17536310.001).

[ISSN] 1541-2016

[Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM

[ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.

[Language] ENG

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDKN1A protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53; 0 / bcl-2-Associated X Protein; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Postlymphoproliferative disorder affecting bone after a renal transplantation.

OBJECTIVE: To illustrate a posttransplant lymphoproliferative lymphoma presenting as a solitary osseous lesion situated in the rib.

CLINICAL FEATURES: A 53-year-old man was referred to a surgical department because of persistent local pain over the lower part of his left posterior hemithorax.

The histological study of the surgically removed tissue revealed diffuse infiltration of the marrow by lymphoid-like cells.

There was evidence of interstitial fibrosis, and further immunohistochemical examination showed the presence of B cells in the specimen confirming the diagnosis of B-cell lymphoma.

CONCLUSION: This case report discusses an unusual presentation of a lymphoma induced by immunosuppressive therapy in a patient who had received an organ transplant.

[MeSH-major] Bone Neoplasms / etiology. Immunosuppression / adverse effects. Kidney Transplantation. Lymphoma, B-Cell / etiology. Ribs

Genetic Alliance. consumer health - Transplantation.

MedlinePlus Health Information. consumer health - Bone Cancer.

MedlinePlus Health Information. consumer health - Kidney Transplantation.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15726037.001).

[ISSN] 1532-6586

[Journal-full-title] Journal of manipulative and physiological therapeutics

[ISO-abbreviation] J Manipulative Physiol Ther

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Marginal zone B-Cell lymphoma among primary B-Cell lymphoma of Waldeyer's ring: histopathologic and immunohistochemical study of 16 tonsillectomy specimens.

Two subtypes of marginal zone B-cell lymphoma (eg, mucosa-associated lymphoid tissue [MALT] type and splenic type) have been reported in the lymph node.

To determine the presence or absence of marginal zone B-cell lymphoma of MALT type and the splenic type among Waldeyer's ring (WR) lymphomas, 16 tonsillectomy specimens were studied.

Ten cases (63%) were marginal zone B-cell lymphoma.

Among marginal zone B-cell lymphoma, 7 were the MALT type and the remaining 3 cases of marginal zone B-cell lymphoma were the splenic type.

Moreover, 4 cases of 7 MALT-type lymphomas contained numerous large cells (diffuse large B-cell lymphoma arising from a low-grade marginal zone B-cell lymphoma of MALT type).

The low incidence of primary mucosa-associated lymphoid tissue type lymphoma of WR in previous reports may be because it is difficult to correctly identify the characteristic histologic findings of MALT-type lymphoma because of the small biopsy size.

[MeSH-major] Lymphoid Tissue / pathology. Lymphoma, B-Cell, Marginal Zone / pathology. Tonsillar Neoplasms / pathology

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18417673.001).

[ISSN] 1066-8969

[Journal-full-title] International journal of surgical pathology

[ISO-abbreviation] Int. J. Surg. Pathol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Biomarkers, Tumor

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Primary lymphoma of the bladder: case report.

[MeSH-major] Antineoplastic Agents, Alkylating / administration & dosage. Cyclophosphamide / administration & dosage. Lymphoma, B-Cell / drug therapy. Lymphoma, Non-Hodgkin / drug therapy. Urinary Bladder Neoplasms / drug therapy

MedlinePlus Health Information. consumer health - Bladder Cancer.

Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16369978.001).

[ISSN] 0361-8609

[Journal-full-title] American journal of hematology

[ISO-abbreviation] Am. J. Hematol.

[Language] eng

[Publication-type] Letter

[Publication-country] United States

[Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 8N3DW7272P / Cyclophosphamide

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Distribution of t(14;18)-positive, putative lymphoma precursor cells among B-cell subsets in healthy individuals.

The t(14;18)(q32;q21) is the characteristic chromosomal translocation of follicular lymphoma (FL).

The aim of this study was to determine the immunophenotypic markers of t(14;18)-positive cells in HI and to relate these features to lymphocyte maturation.

B cells from 10 subjects with t(14;18)-positive and three subjects with t(14;18)-negative peripheral blood mononuclear cells (PBMC) were fluorescence-activated cell sorted for antigen-naïve (CD27(-)), immunoglobulin M (IgM) memory (IgM(+)CD27(+)) and switched memory (IgM(-) CD27(+)) cells. t(14;18)-recombinations were detected by quantitative PCR.

Among PBMC-positive subjects, t(14;18)-frequency was significantly higher in IgM memory (median: 380/10(6)) than in antigen-naïve (median: 16/10(6)) or switched memory (median: 5/10(6)) B cells.

All PBMC-negative subjects nevertheless had detectable t(14;18) in sorted B cells; levels were lower than in PBMC-positive subjects, but had the same relative predominance.

These results suggest that t(14;18) is generated during early B-cell development in the bone marrow and that affected cells may mature and expand in germinal centres. t(14;18)-frequency was highest in IgM memory cells, a B-cell subset that shares immunophenotypic similarities with FL.

The significance of these cells as lymphoma precursors or indicators of lymphoma risk remains to be established.

[MeSH-minor] Clone Cells. Gene Frequency. Genes, Immunoglobulin. Genes, bcl-2. Humans. Immunologic Memory. Immunophenotyping. Lymphoma, Non-Hodgkin / immunology. Polymerase Chain Reaction

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17614821.001).

[ISSN] 0007-1048

[Journal-full-title] British journal of haematology

[ISO-abbreviation] Br. J. Haematol.

[Language] eng

[Grant] United States / Intramural NIH HHS / /

[Publication-type] Journal Article; Research Support, N.I.H., Intramural

[Publication-country] England

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Clinical development of radioimmunotherapy for B-cell non-Hodgkin's lymphoma.

Over the past several decades, several biomolecules have been investigated for their ability to deliver radiation to cancer cells, but antibodies have been the carriers of choice in systemic targeted radionuclide therapy (STaRT).

Food and Drug Administration for the treatment of patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL), and clinical trials have shown that they are effective as monotherapies in the salvage setting, producing response rates that are often higher and durations of response that are often longer than those with chemotherapy.

Escalated doses of these agents can be supported with stem cell transplantation and can produce high rates of complete response and greater survival in patients with relapsed NHL.

[MeSH-major] Antibodies, Monoclonal / therapeutic use. Lymphoma, B-Cell / radiotherapy. Radioimmunotherapy / methods

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16979433.001).

[ISSN] 0360-3016

[Journal-full-title] International journal of radiation oncology, biology, physics

[ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] United States

[Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD20; 0 / Iodine Radioisotopes; 0 / Yttrium Radioisotopes; 0 / ibritumomab tiuxetan; 0 / iodine-131 anti-B1 antibody

[Number-of-references] 45

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Expression of p53, Ki-67, bcl-2, c-erb-2, estrogen, and progesterone receptors in endometrial cancer].

[Transliterated title] Exprese p53, Ki-67, bcl-2, c-erb-2, estrogenového, a progesteronového receptoru v endometriálním karcinomu.

OBJECTIVE: To assess the immunohistochemical expression of p53, bcl-2, c-erb-2, Ki-67, estrogen and progesterone receptors in endometrial cancer patients.

METHODS: We studied 103 cases of primary untreated endometrial carcinoma in which the p53, bcl-2, c-erb-2, Ki-67, estrogen and progesterone receptor antigens were investigated by an immunohistochemical method.

We evaluated the correlations among the immunohistochemical staining assessed by histoscore, and the age, grading, depth of invasion, stage of the neoplasia and extrauterine disease.

p53, bcl-2, c-erb-2, Ki-67, estrogen and progesterone receptors were positive in 49 (48%), 81 (79%).

There was no clear association between immunohistochemical parameters and the age of patients. p53 and Ki-67 overexpression was found to be related to poor grade of differentiation, deeper myometrial invasion, advanced stage of neoplasia and extrauterine spread of disease.

Immunostaining for bcl-2 correlated inversely with FIGO stage, while c-erb-2 was overexpressed in tumors with deeper myometrial invasion.

Estrogen and progesterone receptor positive tumors showed a statistically significant association with clinicopathological parameters of better clinical outcome.

CONCLUSION: The overexpression of p53 and Ki-67 seems to indicate more malignant phenotype, while bcl-2 and c-erb-2 may have a limited role in the identification of high-risk tumors.

Genetic Alliance. consumer health - Endometrial cancer.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18711961.001).

[ISSN] 1210-7832

[Journal-full-title] Ceska gynekologie

[ISO-abbreviation] Ceska Gynekol

[Language] CZE

[Publication-type] English Abstract; Journal Article

[Publication-country] Czech Republic

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 0 / Tumor Suppressor Protein p53; EC 2.7.10.1 / Receptor, ErbB-2

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Bcl-2 expression and p38MAPK activity in cells infected with influenza A virus: impact on virally induced apoptosis and viral replication.

Previous reports have shown that various steps in the influenza A virus life cycle are impaired in cells expressing the antiapoptotic protein Bcl-2 (Bcl-2(+) cells).

We demonstrated a direct link between Bcl-2 and the reduced nuclear export of viral ribonucleoprotein (vRNP) complexes in these cells.

However, despite its negative impact on viral replication, Bcl-2 did not prevent host cells from undergoing virally triggered apoptosis.

In infected Bcl-2(+) cells, activated p38MAPK was found predominantly in the cytoplasm, colocalized with Bcl-2, and both Bcl-2 phosphorylation and virally induced apoptosis were diminished by specific inhibition of p38MAPK activity.

In contrast, in Bcl-2-negative (Bcl-2(-)) cells, which are fully permissive to viral infection, p38MAPK activity was predominantly nuclear, and its inhibition decreased vRNP traffic, phosphorylation of viral nucleoprotein, and virus titers in cell supernatants, suggesting that this kinase also contributes to the regulation of vRNP export and viral replication.

This could explain why in Bcl-2(+) cells, where p38MAPK is active in the cytoplasm, phosphorylating Bcl-2, influenza viral replication is substantially reduced, whereas apoptosis proceeds at rates similar to those observed in Bcl-2(-) cells.

Our findings suggest that the impact of p38MAPK on the influenza virus life cycle and the apoptotic response of host cells to infection depends on whether or not the cells express Bcl-2, highlighting the possibility that the pathological effects of the virus are partly determined by the cell type it targets.

[MeSH-major] Influenza A Virus, H1N1 Subtype / physiology. Kidney / physiology. Proto-Oncogene Proteins c-bcl-2 / genetics. p38 Mitogen-Activated Protein Kinases / metabolism

[MeSH-minor] Animals. Apoptosis. Cell Line. DNA Primers. Dogs. Down-Regulation. Humans. Life Cycle Stages. Plasmids. Polymerase Chain Reaction. RNA, Small Interfering / genetics. Transfection. Virus Replication

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Gen Virol. 2000 Jan;81(Pt 1):135-42 [10640551.001]

[Cites] Proc Natl Acad Sci U S A. 1991 Aug 15;88(16):6961-5 [1871110.001]

[Cites] Life Sci. 2000 Jan 14;66(8):663-73 [10680575.001]

[Cites] Proc Natl Acad Sci U S A. 1995 May 9;92(10):4507-11 [7753834.001]

[Cites] J Virol. 1996 Jan;70(1):663-6 [8523590.001]

[Cites] J Virol. 1997 Dec;71(12):9690-700 [9371635.001]

[Cites] EMBO J. 1998 Jan 2;17(1):288-96 [9427762.001]

[Cites] J Immunol. 1998 May 1;160(9):4175-81 [9574517.001]

[Cites] Am J Respir Cell Mol Biol. 1998 Jun;18(6):794-9 [9618384.001]

[Cites] Virology. 1998 Jun 20;246(1):1-23 [9656989.001]

[Cites] Pharmacol Ther. 1999 May-Jun;82(2-3):389-97 [10454214.001]

[Cites] Cell Mol Life Sci. 1999 Aug 15;55(10):1230-54 [10487205.001]

[Cites] Am J Respir Crit Care Med. 2005 Apr 1;171(7):764-72 [15618464.001]

[Cites] J Infect Dis. 2005 May 15;191(10):1719-29 [15838800.001]

[Cites] J Immunol. 2000 Mar 15;164(6):3222-8 [10706714.001]

[Cites] Biochem Biophys Res Commun. 2000 Nov 30;278(3):753-9 [11095980.001]

[Cites] EMBO J. 2000 Dec 15;19(24):6751-8 [11118210.001]

[Cites] J Virol. 2001 Jan;75(1):408-19 [11119609.001]

[Cites] J Virol. 2001 Mar;75(6):2710-28 [11222695.001]

[Cites] Nat Cell Biol. 2001 Mar;3(3):301-5 [11231581.001]

[Cites] Leukemia. 2001 Jun;15(6):869-74 [11417471.001]

[Cites] J Biol Chem. 2001 Oct 19;276(42):39027-36 [11495898.001]

[Cites] Virus Res. 2002 Mar 20;84(1-2):37-44 [11900837.001]

[Cites] J Gen Virol. 2002 Apr;83(Pt 4):723-34 [11907320.001]

[Cites] Trends Mol Med. 2003 Feb;9(2):46-52 [12615037.001]

[Cites] FASEB J. 2003 Apr;17(6):758-60 [12594179.001]

[Cites] EMBO J. 2003 Jun 2;22(11):2717-28 [12773387.001]

[Cites] Vet Microbiol. 2003 Aug 29;95(1-2):1-13 [12860072.001]

[Cites] Biochem Biophys Res Commun. 2003 Aug 8;307(4):870-6 [12878192.001]

[Cites] Virus Res. 2003 Sep;95(1-2):3-12 [12921991.001]

[Cites] EMBO J. 2003 Sep 15;22(18):4646-55 [12970177.001]

[Cites] J Virol. 2004 Feb;78(3):1263-70 [14722281.001]

[Cites] Appl Microbiol. 1968 Apr;16(4):588-94 [5647517.001]

[Cites] J Gen Virol. 1989 Sep;70 ( Pt 9):2421-31 [2778438.001]

[Cites] J Immunol Methods. 1991 Jun 3;139(2):271-9 [1710634.001]

[Cites] Nature. 1993 Feb 25;361(6414):739-42 [8441470.001]

[Cites] J Cell Biol. 1994 Jan;124(1-2):1-6 [8294493.001]

[Cites] J Virol. 1994 Jun;68(6):3667-73 [8189504.001]

[Cites] Am J Pathol. 1994 Jun;144(6):1195-202 [8203460.001]

[Cites] Antimicrob Agents Chemother. 2000 Jan;44(1):200-4 [10602750.001]

[Cites] J Virol. 2005 Aug;79(16):10147-54 [16051807.001]

[Cites] J Virol. 2005 Sep;79(18):11788-800 [16140756.001]

[Cites] Brain Res Bull. 2006 Feb 15;68(6):406-13 [16459194.001]

[Cites] Cell Microbiol. 2006 Mar;8(3):375-86 [16469051.001]

[Cites] J Biol Chem. 2006 Jul 28;281(30):21353-61 [16714293.001]

[Cites] FASEB J. 2006 Aug;20(10):1683-5 [16790527.001]

[Cites] Intervirology. 2007;50(2):99-107 [17139186.001]

[Cites] Virus Res. 2007 Mar;124(1-2):12-21 [17081640.001]

[Cites] J Virol. 2007 Dec;81(23):12730-9 [17881440.001]

[Cites] PLoS Pathog. 2008 May;4(5):e1000018 [18516228.001]

[Cites] J Virol. 2000 Feb;74(4):1781-6 [10644350.001]

(PMID = 19336399.001).

[ISSN] 0021-9258

[Journal-full-title] The Journal of biological chemistry

[ISO-abbreviation] J. Biol. Chem.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / DNA Primers; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / RNA, Small Interfering; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases

[Other-IDs] NLM/ PMC2708894

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] CD14 and CD169 expression in human lymph nodes and spleen: specific expansion of CD14+CD169- monocyte-derived cells in diffuse large B-cell lymphomas.

The mononuclear phagocyte system of human lymphoid tissue comprises macrophages and dendritic cells (DCs).

The heterogeneity of the non-DC mononuclear phagocyte population in human lymphoid tissue has been little addressed.

Here, we studied the expression of 2 monocyte-derived markers, CD14 and CD169 (sialoadhesin), in reactive human lymphoid tissue as well as in a series of 51 B-cell lymphomas by immunohistochemistry on paraffin-embedded tissue.

We confirmed that lymph node sinusoidal monocyte-derived cells were the only population staining for CD169.

Although most sinusoidal histiocytes also expressed CD14, monocyte-derived cells with phagocytosis such as erythrophagocytosis, anthracosis, or tingible bodies macrophage lacked CD14 and CD169.

Among B-cell lymphomas, splenic marginal zone lymphoma was the only one associated with an expansion of the CD14(+)CD169(+) cells in the cords.

With respect to nodal B-cell lymphomas, CD14(+) cells were rare among B-chronic lymphocytic leukemia, follicular lymphoma (FL), mantle cell lymphoma (MCL).

However, strikingly, we found a strong expansion of CD14(+)CD169(-) cells in numerous diffuse large B-cell lymphomas (DLBCLs), except in cases associated with numerous mitoses, apoptotic bodies, and tingible bodies macrophages.

When cultivated in granulocyte/macrophage colony stimulating factor/interleukin 4, DLBCL purified CD14(+) cells differentiate into plasmacytoid cells, expressing DC-specific intercellular adhesion molecule 3-grabbing nonintegrin, suggesting dendritic cell differentiation potential.

[MeSH-major] Antigens, CD14 / metabolism. Lymph Nodes / metabolism. Lymphoma, B-Cell / metabolism. Lymphoma, Large B-Cell, Diffuse / metabolism. Membrane Glycoproteins / metabolism. Monocytes / metabolism. Receptors, Immunologic / metabolism. Spleen / metabolism

[MeSH-minor] Biomarkers, Tumor / metabolism. Cell Separation. Dendritic Cells / metabolism. Dendritic Cells / pathology. Flow Cytometry. Fluorescent Antibody Technique, Direct. Humans. Immunoenzyme Techniques. Lymphadenitis / metabolism. Lymphadenitis / pathology. Sialic Acid Binding Ig-like Lectin 1

Genetic Alliance. consumer health - B-Cell Lymphomas.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16360418.001).

[ISSN] 0046-8177

[Journal-full-title] Human pathology

[ISO-abbreviation] Hum. Pathol.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Antigens, CD14; 0 / Biomarkers, Tumor; 0 / Membrane Glycoproteins; 0 / Receptors, Immunologic; 0 / SIGLEC1 protein, human; 0 / Sialic Acid Binding Ig-like Lectin 1

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Efficient tumor cell lysis mediated by a Bcl-X(L) specific T cell clone isolated from a breast cancer patient.

Based on the detection of spontaneous immune responses in cancer patients with cancer of different origin, Bcl-X(L) was recently described as a highly interesting tumor antigen recognized by CD8 positive cytotoxic T lymphocytes.

To further characterize Bcl-X(L) as a tumor antigen we isolated and expanded Bcl-X(L) specific T cells from the peripheral blood of a breast cancer patient hosting a strong Bcl-X(L) specific T cell response.

We describe that HLA-A2 restricted Bcl-X(L) specific T cell clones very efficiently lyse peptide pulsed T2 cells.

Furthermore, tumor cell lines of different origin, i.e., breast cancer, colon cancer, and melanoma, are efficiently lysed in an HLA-dependent manner.

Finally, ex vivo-isolated leukemia cells, but not non-malignant B and T cells are killed by Bcl-X(L) specific T cells.

Our data underline Bcl-X(L) as an universal tumor antigen widely applicable in specific anticancer immunotherapy.

[MeSH-major] Antigens, Neoplasm / immunology. Breast Neoplasms / immunology. Neoplasms / immunology. T-Lymphocytes, Cytotoxic / immunology. bcl-X Protein / immunology

[MeSH-minor] Clone Cells. Cytotoxicity, Immunologic. Female. Flow Cytometry. HLA-A2 Antigen. Humans. Reverse Transcriptase Polymerase Chain Reaction

Genetic Alliance. consumer health - Breast Cancer.

MedlinePlus Health Information. consumer health - Breast Cancer.

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16850344.001).

[ISSN] 0340-7004

[Journal-full-title] Cancer immunology, immunotherapy : CII

[ISO-abbreviation] Cancer Immunol. Immunother.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Germany

[Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / HLA-A2 Antigen; 0 / bcl-X Protein

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Requirement for JNK-dependent upregulation of BimL in anti-IgM-induced apoptosis in murine B lymphoma cell lines WEHI-231 and CH31.

The cross-linking of B cell receptor (BCR) undergoes growth arrest, accompanied by apoptosis, in the CH31 and WEHI-231 B lymphoma cells, a model representing primary immature B cells.

In unstimulated cells, BimL protein was complexed with Bcl-x(L) and changed the partner to associate with Bax on the mitochondrial membrane after ligation of BCR, leading to initiation of apoptotic processes.

Retroviral transduction of BimL into WEHI-231 cells overexpressing dominant-negative form of JNK1 (dnJNK1) resulted in a comparable level of apoptotic cells to control cells, whereas the BimL-mediated apoptosis was partially prevented by Bcl-x(L).

[MeSH-major] Apoptosis Regulatory Proteins / genetics. JNK Mitogen-Activated Protein Kinases / metabolism. Lymphoma, B-Cell / metabolism. Membrane Proteins / genetics. Proto-Oncogene Proteins / genetics

[MeSH-minor] Animals. Antibodies, Anti-Idiotypic / administration & dosage. Apoptosis / immunology. Base Sequence. Biological Transport, Active. Cell Line, Tumor. DNA Primers / genetics. Immunoglobulin M. Mice. Protein Isoforms / genetics. Protein Isoforms / metabolism. Receptors, Antigen, B-Cell / metabolism. Recombinant Proteins / genetics. Recombinant Proteins / metabolism. Transduction, Genetic. Up-Regulation. bcl-2-Associated X Protein / metabolism. bcl-X Protein / metabolism

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17007835.001).

[ISSN] 0014-4827

[Journal-full-title] Experimental cell research

[ISO-abbreviation] Exp. Cell Res.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Antibodies, Anti-Idiotypic; 0 / Apoptosis Regulatory Proteins; 0 / Bax protein, mouse; 0 / Bcl-2-like protein 11; 0 / Bcl2l1 protein, mouse; 0 / DNA Primers; 0 / Immunoglobulin M; 0 / Membrane Proteins; 0 / Protein Isoforms; 0 / Proto-Oncogene Proteins; 0 / Receptors, Antigen, B-Cell; 0 / Recombinant Proteins; 0 / bcl-2-Associated X Protein; 0 / bcl-X Protein; EC 2.7.11.24 / JNK Mitogen-Activated Protein Kinases

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] New insights into the molecular biology and targeted therapy of cutaneous T-cell lymphomas.

Cutaneous T-cell lymphoma is an extra-nodal non-Hodgkin lymphoma of mature T cells.

These tumor cells home to and persist in the skin,producing a broad spectrum of clinical entities.

Recent results of basic research on tumor biology and tumor immunology as well as molecular genetics of cutaneous T-cell lymphoma have fostered the development of new therapeutic approaches.

Several clinical trials testing these targeted therapies have shown encouraging results.

This article provides an overview of recent research developments and therapeutic strategies for cutaneous T-cell lymphoma.

[MeSH-major] Antineoplastic Agents / administration & dosage. Drug Delivery Systems / trends. Genetic Therapy / trends. Lymphoma, T-Cell / drug therapy. Lymphoma, T-Cell / physiopathology. Skin Neoplasms / drug therapy. Skin Neoplasms / physiopathology

Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.

MedlinePlus Health Information. consumer health - Genes and Gene Therapy.

MedlinePlus Health Information. consumer health - Skin Cancer.

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16686607.001).

[ISSN] 1610-0379

[Journal-full-title] Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG

[ISO-abbreviation] J Dtsch Dermatol Ges

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] Germany

[Chemical-registry-number] 0 / Antineoplastic Agents

[Number-of-references] 90

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Peripheral blood complete remission after splenic irradiation in mantle-cell lymphoma with 11q22-23 deletion and ATM inactivation.

Mantle Cell Lymphoma (MCL) is a well-known histological and clinical subtype of B-cell non-Hodgkin's Lymphomas.

It is usually characterized by an aggressive disease course, presenting with advanced stage disease at diagnosis and with low response rates to therapy.

We herein report a case of MCL with splenomegaly and peripheral blood involvement as main clinical features.

Mainly advocated mechanisms responsible for this phenomenon are considered direct radiation-induced apoptotic cell death, immune modulation via proportional changes of lymphocyte subsets due to known differences in intrinsic radiosensitivity and a radiation-induced cytokine release.

The peculiar intrinsic radiosensitivity pattern of lymphoid cells could probably be explained by well-defined individual genetic and molecular features.

In this context, among NHLs, MCL subtype has the highest rate of ATM (Ataxia Teleangiectasia Mutated) inactivation.

While the ATM gene is thought to play a key-role in detecting radiation-induced DNA damage (especially Double Strand Breaks), recent in vitro data support the hypothesis that ATM loss may actually contribute to the radiosensitivity of MCL cells.

[MeSH-major] Cell Cycle Proteins / genetics. Chromosome Deletion. Chromosomes, Human, Pair 11. DNA-Binding Proteins / genetics. Lymphoma, Mantle-Cell / genetics. Lymphoma, Mantle-Cell / radiotherapy. Protein-Serine-Threonine Kinases / genetics. Spleen / radiation effects. Tumor Suppressor Proteins / genetics

Genetic Alliance. consumer health - Mantle cell lymphoma.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

University of Turin Instituional Repository AperTO. Full Text from .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Radiother Oncol. 2001 Mar;58(3):235-46 [11230883.001]

[Cites] Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2773-8 [10706620.001]

[Cites] Eur J Cancer. 2002 Feb;38(3):401-8 [11818206.001]

[Cites] Am J Clin Pathol. 2002 Feb;117(2):237-45 [11863220.001]

[Cites] Am J Clin Oncol. 2003 Apr;26(2):178-83 [12714892.001]

[Cites] Proc Natl Acad Sci U S A. 2003 Apr 29;100(9):5372-7 [12697903.001]

[Cites] Oncogene. 2003 Sep 11;22(39):7905-12 [12970738.001]

[Cites] Tumori. 1982 Dec 31;68(6):511-4 [6820205.001]

[Cites] Acta Haematol. 1983;70(1):59-62 [6408868.001]

[Cites] Radiother Oncol. 1985 Aug;4(1):45-54 [3898236.001]

[Cites] Int J Radiat Biol Relat Stud Phys Chem Med. 1985 Dec;48(6):943-61 [3877700.001]

[Cites] Cancer. 1986 Sep 15;58(6):1204-7 [2427184.001]

[Cites] Am J Hematol. 1989 Mar;30(3):188-9 [2916562.001]

[Cites] Eur J Haematol. 1991 Apr;46(4):202-4 [2015875.001]

[Cites] Br J Haematol. 1990 Oct;76(2):305-6 [2094335.001]

[Cites] Eur J Cancer. 1992;28A(10):1729-34 [1389495.001]

[Cites] Am J Hematol. 1994 Jun;46(2):65-71 [8172197.001]

[Cites] Br J Radiol. 1995 Sep;68(813):997-1003 [7496700.001]

[Cites] Leuk Lymphoma. 1997 Jul;26(3-4):395-8 [9322903.001]

[Cites] Semin Hematol. 1999 Apr;36(2):115-27 [10319380.001]

[Cites] Blood Rev. 1999 Sep;13(3):163-70 [10527268.001]

[Cites] Cancer Treat Rev. 2005 May;31(3):159-72 [15923088.001]

[Cites] Lancet Oncol. 2005 Jul;6(7):520-8 [15992701.001]

[Cites] J Clin Oncol. 2005 Sep 10;23(26):6409-14 [16155027.001]

[Cites] Mutat Res. 2006 May 11;597(1-2):113-8 [16413041.001]

[Cites] Blood. 1999 Nov 1;94(9):3262-4 [10556216.001]

[Cites] Blood. 2002 Jan 1;99(1):238-44 [11756177.001]

(PMID = 16956411.001).

[ISSN] 1748-717X

[Journal-full-title] Radiation oncology (London, England)

[ISO-abbreviation] Radiat Oncol

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

[Chemical-registry-number] 0 / Biomarkers; 0 / Cell Cycle Proteins; 0 / DNA-Binding Proteins; 0 / Tumor Suppressor Proteins; EC 2.7.11.1 / ATM protein, human; EC 2.7.11.1 / Ataxia Telangiectasia Mutated Proteins; EC 2.7.11.1 / Protein-Serine-Threonine Kinases

[Other-IDs] NLM/ PMC1569379

[General-notes] NLM/ Original DateCompleted: 20070726

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Plasmablastic lymphoma: Cytologic findings in 5 cases with unusual presentation.

BACKGROUND: Plasmablastic lymphoma (PBL) is a rare form of non-Hodgkin lymphoma that was once believed to occur primarily in the oral cavity of human immunodeficiency virus-positive individuals.

The presence of the following was evaluated: cellularity, plasmablastic cells, background necrosis (BN), single-cell necrosis (SCN), lymphoglandular bodies (LGB), tingible-body macrophages (TBM), 3-dimensional clusters/sheets, and cytoplasmic vacuoles.

Two patients had the acquired immunodeficiency syndrome and 3 had second non-PBL related malignancies including endometrial carcinoma, lung adenocarcinoma, and small lymphocytic lymphoma.

The most common cytologic features were hypercellularity (80%), plasmablastic cells (73%), SCN (73%), BN (87%), and LGB (66%).

These include hypercellular specimens with abundant plasmablastic cells, LGB, SCN, and BN.

However, although these findings may suggest PBL, a definitive diagnosis requires adjunctive studies including immunohistochemistry and flow cytometry.

[MeSH-major] Lymphoma, Non-Hodgkin / metabolism. Lymphoma, Non-Hodgkin / pathology

HIV InSite. treatment guidelines - Human Herpesvirus-8 .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] (c) 2008 American Cancer Society.

(PMID = 18683216.001).

[ISSN] 0008-543X

[Journal-full-title] Cancer

[ISO-abbreviation] Cancer

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Stem cell transplantation in childhood non-Hodgkin's lymphomas.

Despite the high cure rates achieved with intensified primary therapies for childhood non-Hodgkin's lymphomas (NHL), the prognosis for children with relapsed or refractory disease is poor.

Dose intensification followed by stem cell transplantation has been used in these circumstances and may provide a curative treatment option for these patients, but the number of children treated using this approach is relatively small and its effectiveness has been difficult to judge.

We summarize the current experience for stem cell transplantation in childhood NHL and offer our recommendations.

[MeSH-major] Hematopoietic Stem Cell Transplantation. Lymphoma, Non-Hodgkin / therapy

[MeSH-minor] Child. Clinical Trials as Topic. Humans. Lymphoma, B-Cell / therapy. Lymphoma, Large-Cell, Anaplastic / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

Genetic Alliance. consumer health - Transplantation.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Blood. 2005 Feb 15;105(4):1622-31 [15507526.001]

[Cites] J Clin Oncol. 1994 May;12(5):899-908 [8164040.001]

[Cites] J Clin Oncol. 2004 Jun 1;22(11):2172-6 [15169805.001]

[Cites] Blood. 2003 Dec 1;102(12):3871-9 [12933571.001]

[Cites] Blood. 2007 Apr 1;109(7):2773-80 [17132719.001]

[Cites] J Clin Oncol. 2001 Jun 1;19(11):2927-36 [11387366.001]

[Cites] Blood. 2000 Jan 15;95(2):416-21 [10627444.001]

[Cites] J Clin Oncol. 1995 Feb;13(2):359-72 [7844597.001]

[Cites] Blood. 2006 May 15;107(10):4047-52 [16424389.001]

[Cites] Int J Hematol. 2006 Jan;83(1):66-73 [16443556.001]

[Cites] J Clin Oncol. 1999 Mar;17(3):825-31 [10071273.001]

[Cites] Ann Oncol. 1997;8 Suppl 1:37-42 [9187427.001]

[Cites] Ann Oncol. 2000 Jan;11(1):53-8 [10690387.001]

[Cites] Br J Haematol. 2006 Apr;133(2):176-82 [16611309.001]

[Cites] Br J Haematol. 2006 Mar;132(5):594-7 [16445832.001]

[Cites] Blood. 2005 Feb 1;105(3):948-58 [15486066.001]

[Cites] J Clin Oncol. 2006 Jan 20;24(3):491-9 [16421426.001]

[Cites] Am J Clin Pathol. 2004 Apr;121(4):496-506 [15080301.001]

[Cites] Semin Oncol. 2009 Oct;36(5):381-418 [19835736.001]

[Cites] Haematologica. 2007 Nov;92(11):1533-48 [18024402.001]

[Cites] J Clin Oncol. 1996 Apr;14(4):1252-61 [8648381.001]

[Cites] Blood. 2001 Jun 1;97(11):3370-9 [11369626.001]

[Cites] Blood. 1999 Jun 1;93(11):3913-21 [10339500.001]

[Cites] J Clin Oncol. 1997 Feb;15(2):509-17 [9053472.001]

[Cites] Bone Marrow Transplant. 2003 Aug;32(3):317-24 [12858205.001]

[Cites] Bone Marrow Transplant. 1999 Mar;23(5):437-42 [10100556.001]

[Cites] J Clin Oncol. 1993 Jun;11(6):1024-32 [8501488.001]

[Cites] Blood. 2007 Apr 1;109(7):2736-43 [17138821.001]

[Cites] Bone Marrow Transplant. 2002 May;29(9):769-75 [12040475.001]

[Cites] Ann Oncol. 1999 Dec;10(12):1419-32 [10643532.001]

[Cites] Ann Oncol. 2006 Jan;17(1):123-30 [16236753.001]

[Cites] Biol Blood Marrow Transplant. 2010 Feb;16(2):223-30 [19800015.001]

[Cites] Bone Marrow Transplant. 1995 Mar;15(3):353-9 [7599558.001]

[Cites] J Clin Oncol. 2006 Jul 1;24(19):3121-7 [16754935.001]

[Cites] Br J Haematol. 2001 Sep;114(4):741-60 [11564061.001]

[Cites] Blood. 1997 Oct 15;90(8):2921-30 [9376572.001]

[Cites] J Clin Oncol. 2009 Jul 10;27(20):3363-9 [19433688.001]

[Cites] Br J Haematol. 2005 Oct;131(1):39-49 [16173961.001]

[Cites] Blood. 2008 Jan 15;111(2):537-43 [17971487.001]

[Cites] Blood. 2008 Feb 1;111(3):1560-6 [17957029.001]

[Cites] Nature. 2000 Feb 3;403(6769):503-11 [10676951.001]

[Cites] Blood. 2004 Feb 1;103(3):777-83 [12907446.001]

[Cites] Br J Haematol. 2009 Jan;144(1):24-40 [19087093.001]

[Cites] Leukemia. 2005 Jun;19(6):945-52 [15800666.001]

[Cites] Rev Prat. 1993 Sep 1;43(13):1665-8 [8303185.001]

[Cites] Bone Marrow Transplant. 2005 Sep;36(5):437-41 [15980879.001]

[Cites] Ann Hematol. 2006 Nov;85(11):787-94 [16932891.001]

[Cites] Blood. 2003 Apr 1;101(7):2476-82 [12456505.001]

[Cites] J Clin Oncol. 2009 Oct 20;27(30):5056-61 [19738127.001]

[Cites] Blood. 2004 Sep 15;104(6):1624-30 [15178574.001]

[Cites] Bone Marrow Transplant. 2003 Apr;31(8):667-78 [12692607.001]

[Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]

[Cites] Cancer. 2003 Sep 15;98(6):1283-91 [12973853.001]

[Cites] Blood. 2007 Oct 15;110(8):2838-45 [17609424.001]

[Cites] J Clin Oncol. 2003 Mar 1;21(5):897-906 [12610191.001]

[Cites] Pediatr Blood Cancer. 2008 Sep;51(3):369-74 [18493992.001]

[Cites] Leukemia. 2007 Dec;21(12):2563-6 [17597802.001]

[Cites] Blood. 2001 Jun 15;97(12):3699-706 [11389005.001]

[Cites] Cancer. 2005 Nov 15;104(10):2133-40 [16211546.001]

[Cites] Lancet Oncol. 2006 May;7(5):379-91 [16648042.001]

[Cites] J Clin Oncol. 2005 Apr 1;23(10):2240-7 [15800314.001]

[Cites] Br J Haematol. 2006 Jun;133(6):634-7 [16704438.001]

(PMID = 20661786.001).

[ISSN] 1558-822X

[Journal-full-title] Current hematologic malignancy reports

[ISO-abbreviation] Curr Hematol Malig Rep

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] United States

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Association of VEGF genetic polymorphisms with the clinical characteristics of non-Hodgkin's lymphoma.

We investigated the possible associations of two polymorphisms (-2578C/A and +936C/T) in the VEGF gene with the clinicopathologic parameters for patients with non-Hodgkin's lymphoma (NHL).

RESULTS: The -2578A allele was significantly associated with less frequent clinical staging III, IV and bone marrow involvement (The odds ratio (OR) 0.59; 95% confidence interval (CI) 0.43-0.82; and OR 0.66; 95% CI 0.48-0.91, respectively).

The TT genotype of the +936C/T polymorphism was significantly associated with less frequent T cell histological type, clinical staging III, IV and bone marrow involvement (OR 0.25; 95% CI 0.07-0.89; OR 0.37; 95% CI 0.15-0.89; and OR 0.31; 95% CI 0.10-0.96, respectively).

The +936 T allele was marginally associated with less frequent bone marrow involvement and with Clinical staging III, IV (OR 0.71; 95% CI 0.49-1.01; and OR 0.70; 95% CI 0.49-1.00, respectively).

None of the evaluated genotypes of -2578C/A was significantly associated with the gender, age, tumor size, B symptoms and immunohistological subtype.

[MeSH-major] Lymphoma, Non-Hodgkin / genetics. Vascular Endothelial Growth Factor A / genetics

[MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Genotype. Humans. Male. Middle Aged. Neoplasm Staging. Polymorphism, Genetic

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Clin Cancer Res. 2005 May 15;11(10):3647-53 [15897560.001]

[Cites] J Cancer Res Clin Oncol. 2008 Mar;134(3):381-7 [17694324.001]

[Cites] Eur Urol. 2007 Oct;52(4):1147-55 [17287073.001]

[Cites] J Cancer Res Clin Oncol. 2007 Oct;133(10):787-91 [17564725.001]

[Cites] Crit Rev Oncol Hematol. 2007 May;62(2):105-18 [17188504.001]

[Cites] Nucleic Acids Res. 1988 Feb 11;16(3):1215 [3344216.001]

[Cites] Gynecol Oncol. 2007 May;105(2):385-9 [17289129.001]

[Cites] Endocr Rev. 1997 Feb;18(1):4-25 [9034784.001]

[Cites] Clin Cancer Res. 2007 Feb 1;13(3):898-901 [17289883.001]

[Cites] Nat Med. 2003 Jun;9(6):669-76 [12778165.001]

[Cites] J Surg Oncol. 2006 Dec 1;94(7):624-30 [17111394.001]

[Cites] J Vasc Res. 2000 Nov-Dec;37(6):443-8 [11146397.001]

[Cites] Cytokine. 2000 Aug;12(8):1232-5 [10930302.001]

[Cites] Semin Oncol. 2005 Feb;32(1 Suppl 1):S36-43 [15786024.001]

[Cites] Leuk Lymphoma. 2007 Mar;48(3):584-95 [17454603.001]

[Cites] Leuk Lymphoma. 2003 Dec;44(12):2089-93 [14959852.001]

[Cites] Cancer Epidemiol Biomarkers Prev. 2006 Jun;15(6):1148-52 [16775174.001]

[Cites] Appl Immunohistochem Mol Morphol. 2002 Dec;10(4):316-21 [12607599.001]

[Cites] Lung Cancer. 2004 Dec;46(3):293-8 [15541813.001]

[Cites] Cancer Res. 2002 Jun 15;62(12):3369-72 [12067976.001]

[Cites] Clin Cancer Res. 2005 Jan 1;11(1):154-61 [15671540.001]

[Cites] Cancer Res. 2003 Feb 15;63(4):812-6 [12591731.001]

[Cites] Ann Diagn Pathol. 2003 Feb;7(1):1-8 [12616467.001]

[Cites] Blood. 2000 Dec 1;96(12):3712-8 [11090051.001]

[Cites] Cancer Epidemiol Biomarkers Prev. 2005 Mar;14(3):571-5 [15767331.001]

[Cites] Genes Immun. 2002 Jun;3(4):229-32 [12058259.001]

[Cites] Urology. 2005 Jan;65(1):70-5 [15667866.001]

[Cites] Int J Cancer. 2003 Sep 10;106(4):468-71 [12845639.001]

(PMID = 19649652.001).

[ISSN] 1432-1335

[Journal-full-title] Journal of cancer research and clinical oncology

[ISO-abbreviation] J. Cancer Res. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Germany

[Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

CpG 7909, acting through the TLR9 receptor present in B cells and plasmacytoid dendritic cells, stimulates human B-cell proliferation, enhances antigen-specific antibody production and induces interferon-alpha production, interleukin-10 secretion and natural killer cell activity.

In 2002, GlaxoSmithKline (GSK) was granted a worldwide, non-exclusive licence to Coley's CpG immunostimulatory oligonucleotides, including CpG 7909 [VaxImmune], for their use as adjuvants for cancer vaccines.

A phase I/II trial in patients with NHL has also been conducted in 24 patients with relapsed or refractory disease at the University of Iowa.

These trials are evaluating CpG 7909 in combination with chemotherapy versus chemotherapy alone as a first-line treatment for patients with advanced (stage IIIb or IV) non-small-cell lung cancer (NSCLC).

[MeSH-major] Lymphoma, Non-Hodgkin / drug therapy. Oligodeoxyribonucleotides / administration & dosage. Oligodeoxyribonucleotides / adverse effects

[MeSH-minor] Adjuvants, Immunologic / administration & dosage. Adjuvants, Immunologic / adverse effects. Anthrax Vaccines / administration & dosage. Anthrax Vaccines / adverse effects. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal / adverse effects. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / adverse effects. Clinical Trials, Phase I as Topic. Humans. Rituximab. Toll-Like Receptor 9 / agonists

Hazardous Substances Data Bank. RITUXIMAB .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16922592.001).

[ISSN] 1174-5886

[Journal-full-title] Drugs in R&D

[ISO-abbreviation] Drugs R D

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] New Zealand

[Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Anthrax Vaccines; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / Oligodeoxyribonucleotides; 0 / ProMune; 0 / TLR9 protein, human; 0 / Toll-Like Receptor 9; 4F4X42SYQ6 / Rituximab

[Number-of-references] 14

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Regression of large B-cell non-Hodgkin's lymphoma of stomach with HAART: case report and review.

[MeSH-major] Antiretroviral Therapy, Highly Active. Lymphoma, AIDS-Related / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Non-Hodgkin / drug therapy. Stomach Neoplasms / drug therapy

MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.

MedlinePlus Health Information. consumer health - Stomach Cancer.

HIV InSite. treatment guidelines - Human Herpesvirus-8 .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16886274.001).

[ISSN] 1042-8194

[Journal-full-title] Leukemia & lymphoma

[ISO-abbreviation] Leuk. Lymphoma

[Language] eng

[Publication-type] Case Reports; Letter

[Publication-country] England

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

OBJECTIVE: It has been reported that high-dose cytarabine (HD-AraC) was very effective for childhood hematological malignancies, especially for improving the long-term survival of high-risk acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and T-cell lymphoid malignancies (T-ALL, T-cell non-Hodgkin's lymphoma).

METHODS: The drug levels of Ara-C in plasma and cerebrospinal fluid were detected with HPLC while HD-AraC was used, the expression of deoxycytidine kinase (dCK) and cytidine deaminase (CDA) mRNA in human leukemia cell lines and the bone marrow cells were investigated in 48 cases of childhood hematological malignancies with RT-PCR methods, and the relationship between the expression of these enzymes mRNA and the outcome of the patients was analyzed. RESULTS:.

There were no significant differences in expressions of dCK in T-ALL and B lineage ALL. (3) In vitro study found that the expressions of dCK and CDA mRNA did not change in leukemia cell lines incubated at different doses and times of Ara-C.

[MeSH-minor] Child. Cytidine Deaminase / genetics. Deoxycytidine Kinase / genetics. Gene Expression. Humans. Leukemia, Myeloid, Acute / drug therapy. Leukemia, Myeloid, Acute / genetics. Leukemia, Myeloid, Acute / metabolism. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / genetics. Lymphoma, Non-Hodgkin / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism

MedlinePlus Health Information. consumer health - Leukemia.

Hazardous Substances Data Bank. CYTARABINE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19099730.001).

[ISSN] 0578-1310

[Journal-full-title] Zhonghua er ke za zhi = Chinese journal of pediatrics

[ISO-abbreviation] Zhonghua Er Ke Za Zhi

[Language] chi

[Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] China

[Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 04079A1RDZ / Cytarabine; EC 2.7.1.74 / Deoxycytidine Kinase; EC 3.5.4.5 / Cytidine Deaminase

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [A case of secondary non-Hodgkin's lymphoma of the colon after the treatment for Hodgkin's disease].

[MeSH-major] Colonic Neoplasms / etiology. Hodgkin Disease / therapy. Lymphoma, Non-Hodgkin / etiology. Neoplasms, Second Primary / etiology

[MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Female. Humans. Peripheral Blood Stem Cell Transplantation. Prednisone / administration & dosage. Procarbazine / administration & dosage. Radiotherapy Dosage. Remission Induction. Vincristine / administration & dosage

MedlinePlus Health Information. consumer health - Hodgkin Disease.

Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

Hazardous Substances Data Bank. PREDNISONE .

Hazardous Substances Data Bank. VINCRISTINE .

Hazardous Substances Data Bank. PROCARBAZINE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15682817.001).

[ISSN] 0446-6586

[Journal-full-title] Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology

[ISO-abbreviation] Nihon Shokakibyo Gakkai Zasshi

[Language] jpn

[Publication-type] Case Reports; Journal Article

[Publication-country] Japan

[Chemical-registry-number] 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; COPP protocol

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] B cell lymphomas express CX3CR1 a non-B cell lineage adhesion molecule.

To study the differential expression of cell membrane-bound receptors and their potential role in growth and/or survival of the tumor cells, highly purified follicular lymphoma cells were analyzed, using gene expression analysis, and compared to non-malignant B cell populations.

Filtering the genome for overexpressed genes coding for cell membrane-bound proteins/receptors resulted in a hit list of 27 identified genes.

Among these, we have focused on the aberrant over expression of CX3CR1, in different types of B cell lymphoma, as compared to non-malignant B cells.

We show that CX3CR1, which normally is not expressed on B cells, is expressed both at the mRNA and protein level in several subtypes of lymphoma.

CX3CR1 has also shown to be involved in the homing to specific tissues that express the ligand, CX3CL1, in breast and prostate cancer and may thus be involved in dissemination of lymphoma.

[MeSH-major] B-Lymphocytes / immunology. Lymphoma, Follicular / immunology. Lymphoma, Mantle-Cell / immunology. Palatine Tonsil / immunology. Receptors, Chemokine / analysis

[MeSH-minor] Cell Separation. Flow Cytometry. Gene Expression Profiling / methods. Gene Expression Regulation, Neoplastic. Humans. Oligonucleotide Array Sequence Analysis. RNA, Messenger / analysis

Genetic Alliance. consumer health - B-Cell Lymphomas.

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18060687.001).

[ISSN] 0304-3835

[Journal-full-title] Cancer letters

[ISO-abbreviation] Cancer Lett.

[Language] eng

[Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Ireland

[Chemical-registry-number] 0 / CX3CR1 protein, human; 0 / RNA, Messenger; 0 / Receptors, Chemokine

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Bcl-2 inhibitors potentiate the cytotoxic effects of radiation in Bcl-2 overexpressing radioresistant tumor cells.

PURPOSE: Bcl-2, an inhibitor of apoptosis frequently shows elevated expression in human tumors, thus resulting in resistance to radiation therapy.

Therefore, inhibiting Bcl-2 function may enhance the radiosensitivity of tumor cells.

Tetrocarcin A (TC-A) and bcl-2 antisense oligonucleotides exhibit antitumor activity by inhibiting Bcl-2 function and transcription, respectively.

We investigated whether these antitumor agents would enhance the cytotoxic effects of radiation in tumor cells overexpressing Bcl-2.

METHODS AND MATERIALS: We used HeLa/bcl-2 cells, a stable Bcl-2-expressing cell line derived from wild-type HeLa (HeLa/wt) cells.

Cells were incubated with TC-A and bcl-2 antisense oligonucleotides for 24 h after irradiation, and cell viability was then determined.

Apoptotic cells were quantified by flow cytometric assay.

RESULTS: The HeLa/bcl-2 cells were more resistant to radiation than HeLa/wt cells.

At concentrations that are not inherently cytotoxic, both TC-A and bcl-2 antisense oligonucleotides increased the cytotoxic effects of radiation in HeLa/bcl-2 cells, but not in HeLa/wt cells.

However, in HeLa/bcl-2 cells, additional treatment with TC-A in combination with radiation did not significantly increase apoptosis.

CONCLUSIONS: The present results suggest that TC-A and bcl-2 antisense oligonucleotides reduce radioresistance of tumor cells overexpressing Bcl-2.

Therefore, a combination of radiotherapy and Bcl-2 inhibitors may prove to be a useful therapeutic approach for treating tumors that overexpress Bcl-2.

[MeSH-major] Aminoglycosides / pharmacology. Apoptosis. Oligonucleotides, Antisense / pharmacology. Proto-Oncogene Proteins c-bcl-2 / antagonists & inhibitors. Radiation Tolerance / drug effects. Radiation-Sensitizing Agents / pharmacology

[MeSH-minor] Analysis of Variance. Cell Survival / drug effects. Cell Survival / radiation effects. HeLa Cells / drug effects. HeLa Cells / metabolism. HeLa Cells / radiation effects. Humans. RNA, Messenger / antagonists & inhibitors. Tumor Stem Cell Assay

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15667975.001).

[ISSN] 0360-3016

[Journal-full-title] International journal of radiation oncology, biology, physics

[ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Aminoglycosides; 0 / Oligonucleotides, Antisense; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / RNA, Messenger; 0 / Radiation-Sensitizing Agents; 73666-84-9 / tetrocarcin A

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Personalized immunotherapy for the treatment of non-Hodgkin's lymphoma: a promising approach.

In patients with B-cell lymphomas, particularly indolent lymphoma, the use of passive immunotherapy, such as the anti-CD20 monoclonal antibody rituximab, has made an impressive impact on patient outcome.

Personalized immunotherapy, a method that triggers the immune system to mount a response against tumor cells, has shown promising results in early clinical trials in hematologic malignancies.

Currently, 3 large phase III studies are evaluating the efficacy and safety of personalized immunotherapy in patients with follicular lymphoma.

It is hoped that the results of these studies will lead to the incorporation of this promising approach into the standard treatment of patients with lymphoma.

[MeSH-major] Cancer Vaccines. Hodgkin Disease / immunology. Immunotherapy / methods

[MeSH-minor] Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Clinical Trials as Topic. Combined Modality Therapy. Granulocyte-Macrophage Colony-Stimulating Factor / therapeutic use. Humans

MedlinePlus Health Information. consumer health - Hodgkin Disease.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16447298.001).

[ISSN] 0278-0232

[Journal-full-title] Hematological oncology

[ISO-abbreviation] Hematol Oncol

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] England

[Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cancer Vaccines; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor

[Number-of-references] 64

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Vaccinia virus anti-apoptotic F1L is a novel Bcl-2-like domain-swapped dimer that binds a highly selective subset of BH3-containing death ligands.

Some viruses express proteins homologous in sequence and function to mammalian pro-survival Bcl-2 proteins.

Anti-apoptotic F1L expressed by vaccinia virus is essential for survival of infected cells, but it bears no discernable sequence homology to proteins other than its immediate orthologues in related pox viruses.

Here we report that the crystal structure of F1L reveals a Bcl-2-like fold with an unusual N-terminal extension.

Structural comparison of F1L with other Bcl-2 family members reveals a novel sequence signature that redefines the BH4 domain as a structural motif present in both pro- and anti-apoptotic Bcl-2 members, including viral Bcl-2-like proteins.

[MeSH-major] Protein Structure, Quaternary. Protein Structure, Tertiary. Proto-Oncogene Proteins c-bcl-2 / chemistry. Viral Proteins / chemistry. Viral Proteins / metabolism

COS Scholar Universe. author profiles.

Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .

Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18551131.001).

[ISSN] 1350-9047

[Journal-full-title] Cell death and differentiation

[ISO-abbreviation] Cell Death Differ.

[Language] eng

[Databank-accession-numbers] PDB/ 2VTY

[Grant] United States / NCI NIH HHS / CA / CA43540; United States / NCI NIH HHS / CA / CA80188

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / F1L protein, vaccinia virus; 0 / Ligands; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Recombinant Proteins; 0 / Viral Proteins

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Overexpression of antiapoptotic members of the Bcl-2 family is observed in approximately 80% of B-cell lymphomas, contributing to intrinsic and acquired drug resistance.

ABT-737 is a BH3-only mimetic and potent inhibitor of the antiapoptotic Bcl-2 family members Bcl-2, Bcl-X(L), and Bcl-w.

In vitro, ABT-737 exhibited concentration-dependent cytotoxicity against a broad panel of lymphoma cell lines including mantle cell lymphoma (MCL) and diffuse large B-cell lymphoma (DLBCL).

ABT-737 showed synergism when combined with the proteasome inhibitors bortezomib or carfilzomib in select lymphoma cell lines and induced potent mitochondrial membrane depolarization and apoptosis when combined with either.

ABT-737 plus bortezomib also induced significant apoptosis in primary samples of MCL, DLBCL, and chronic lymphocytic leukemia (CLL) but no significant cytotoxic effect was observed in peripheral blood mononuclear cells from healthy donors.

Collectively, these data suggest that ABT-737 alone or in combination with a proteasome inhibitor represents a novel and potentially important platform for the treatment of B-cell malignancies.

[MeSH-major] Antineoplastic Agents / pharmacology. Biphenyl Compounds / pharmacology. Enzyme Inhibitors / pharmacology. Lymphoma / enzymology. Lymphoma / pathology. Molecular Mimicry / drug effects. Nitrophenols / pharmacology. Proteasome Inhibitors. Sulfonamides / pharmacology

[MeSH-minor] Animals. Boronic Acids / pharmacology. Bortezomib. Cell Death / drug effects. Cell Line, Tumor. Dose-Response Relationship, Drug. Drug Resistance, Neoplasm / drug effects. Drug Synergism. Health. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Leukocytes, Mononuclear / drug effects. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Mantle-Cell / pathology. Membrane Potential, Mitochondrial / drug effects. Mice. Microscopy, Confocal. Piperazines / pharmacology. Proto-Oncogene Proteins c-bcl-2 / metabolism. Pyrazines / pharmacology. Tissue Donors. Xenograft Model Antitumor Assays

MedlinePlus Health Information. consumer health - Lymphoma.

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. BORTEZOMIB .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18591385.001).

[ISSN] 1528-0020

[Journal-full-title] Blood

[ISO-abbreviation] Blood

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / ABT-737; 0 / Antineoplastic Agents; 0 / Biphenyl Compounds; 0 / Boronic Acids; 0 / Enzyme Inhibitors; 0 / Nitrophenols; 0 / Piperazines; 0 / Proteasome Inhibitors; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Pyrazines; 0 / Sulfonamides; 69G8BD63PP / Bortezomib

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Aberrant somatic hypermutations in thyroid lymphomas.

To determine a possible role of aberrant somatic hypermutation (ASHM) in the pathogenesis of thyroid lymphoma (TL), mutational status of genes affected by ASHM, including c-MYC, PIM-1, PAX-5 and RhoH/TTF, was analyzed.

Tumor specimens from 33 patients with thyroid B-cell lymphoma and 14 with chronic lymphocytic thyroiditis (CLTH), an autoimmune thyroiditis known to provide a basis for TL development, was examined.

Occurrence of ASHM in PIM-1, RhoH/TTF, and c-MYC was a constant finding in follicular lymphoma (FL) (all of 11 cases) but not so frequent in diffuse large B-cell lymphoma (DLBCL) (4 (33.3%) of 12 cases) and Marginal zone B-cell lymphoma (MZBCL) (1 (10.0%) of 10 cases).

[MeSH-major] Lymphoma, Non-Hodgkin / genetics. Mutation. Thyroid Neoplasms / genetics

MedlinePlus Health Information. consumer health - Thyroid Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19019431.001).

[ISSN] 1873-5835

[Journal-full-title] Leukemia research

[ISO-abbreviation] Leuk. Res.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Expression of a soluble decoy receptor 3 in patients with diffuse large B-cell lymphoma predicts clinical outcome.

It is regarded as a decoy receptor released from tumor cells to escape host immune response by neutralizing the cytotoxic and immunomodulatory effects of FasL, LIGHT and TL1A.

Overexpression of DcR3 has been observed in several human malignancies; however, only limited information exists on the role of DcR3 in non-Hodgkin lymphoma especially for B-cell origin.

In the current study, the expression profile of DcR3 was analyzed by RT-PCR and immunohistochemistry (IHC) in a set of lymphoma cell lines including T-cell and B-cell lymphomas.

The result demonstrated that overexpression of DcR3 was detected in most T-cell lymphoma cells, which was consistent with previous reports.

Interestingly, overexpression of DcR3 was also detected both in the B-cell lymphoma cell lines and diffuse large B cell lymphoma (DLBCL) patients.

An in vitro study showed that neutralization of DcR3 increased the percentage of doxorubicin-mediated apoptosis in two B-cell lymphoma cell lines, which indicated the possibility of DcR3 mediated chemo-resistance in B-cell lymphomas.

We suggest that overexpression of DcR3 is associated with a worse prognosis in DLBCL and the possible mechanism may act through the increase of chemo-resistance of lymphoma cells.

[MeSH-major] Biomarkers, Tumor / analysis. Drug Resistance, Neoplasm / genetics. Lymphoma, Large B-Cell, Diffuse / metabolism. Receptors, Tumor Necrosis Factor, Member 6b / biosynthesis

[MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Female. Gene Expression. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Lymphoma, T-Cell / metabolism. Lymphoma, T-Cell / mortality. Lymphoma, T-Cell / pathology. Male. Middle Aged. Prednisone / therapeutic use. Prognosis. Reverse Transcriptase Polymerase Chain Reaction. Vincristine / therapeutic use

Genetic Alliance. consumer health - Large B cell diffuse lymphoma.

Hazardous Substances Data Bank. DOXORUBICIN .

Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

Hazardous Substances Data Bank. PREDNISONE .

Hazardous Substances Data Bank. VINCRISTINE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18695885.001).

[ISSN] 1019-6439

[Journal-full-title] International journal of oncology

[ISO-abbreviation] Int. J. Oncol.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Greece

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Tumor Necrosis Factor, Member 6b; 0 / TNFRSF6B protein, human; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Blood viscosity in patients with diffuse large B cell non-Hodgkin's lymphoma.

The aim of the study was to evaluate blood viscosity as possible marker of disease progression in patients with newly diagnosed non-Hodgkin's lymphoma (NHL).

[MeSH-major] Blood Viscosity. Lymphoma, B-Cell / blood. Lymphoma, Large B-Cell, Diffuse / blood

Genetic Alliance. consumer health - Large B cell diffuse lymphoma.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17285120.001).

[ISSN] 1812-9269

[Journal-full-title] Experimental oncology

[ISO-abbreviation] Exp. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] Ukraine

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Autologous hematopoietic stem cell transplantation for aggressive B-cell non-Hodgkin's lymphoma].

To evaluate the results of high-dose chemotherapy (HDT) and autologous hematopoietic stem cell transplantation (ASCT) in patients with diffuse B-cell aggressive non-Hodgkin's lymphoma(NHL).

The 5-year probability of disease-free survival for patients in the low-risk group and in the high-risk group was 68.8% and 60.0%,respectively (p = 0.9 6).

[MeSH-major] Hematopoietic Stem Cell Transplantation. Lymphoma, B-Cell / therapy. Lymphoma, Large B-Cell, Diffuse / therapy. Transplantation, Autologous

[MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Disease-Free Survival. Drug Administration Schedule. Etoposide / administration & dosage. Female. Humans. Male. Middle Aged. Nitrosourea Compounds / administration & dosage. Remission Induction. Treatment Outcome

Genetic Alliance. consumer health - Transplantation.

Hazardous Substances Data Bank. CYTARABINE .

Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

Hazardous Substances Data Bank. ETOPOSIDE .

Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16352929.001).

[ISSN] 0385-0684

[Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy

[ISO-abbreviation] Gan To Kagaku Ryoho

[Language] jpn

[Publication-type] English Abstract; Journal Article

[Publication-country] Japan

[Chemical-registry-number] 0 / Nitrosourea Compounds; 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin; RYH2T97J77 / ranimustine

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Notch-regulation upon Dll4-stimulation of TGFb-induced apoptosis and gene expression in human B-cell non-Hodgkin lymphomas.

Notch-signalling has been implicated as a pathogenetic factor and a therapeutical target in T-cell leukaemias and in some lymphomas of B-cell origin.

Our aim was to investigate the role of Notch-signalling in apoptosis regulation in human non-Hodgkin B-cell lymphoma (B-NHL) cell lines and in primary chronic lymhocytic leukaemia (CLL) cells using Delta-like 4 (Dll4) ligand mediated Notch activation and gamma-secretase inhibitor (GSI) mediated Notch inhibition in vitro.

Modulation of Notch-signalling by itself did not change the rate of apoptosis in B-NHL cell lines and in CLL cells.

TGFb-induced apoptosis was decreased - but not completely abolished - by GSI in TGFb-sensitive cell lines, but resistance to the apoptotic effects of TGFb were not reversed by Notch activation or inhibition.

We identified Hairy/Enhancer of Split (HES)-1 as a TGFb target gene in selected - TGFb-sensitive - B-NHL cell lines.

[MeSH-major] Apoptosis / drug effects. Intercellular Signaling Peptides and Proteins / pharmacology. Lymphoma, B-Cell / pathology. Receptors, Notch / physiology. Transforming Growth Factor beta / pharmacology

[MeSH-minor] Amyloid Precursor Protein Secretases / antagonists & inhibitors. Basic Helix-Loop-Helix Transcription Factors / genetics. Cell Line, Tumor. Dipeptides / pharmacology. Gene Expression Regulation, Neoplastic / drug effects. Homeodomain Proteins / genetics. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Repressor Proteins / genetics. Signal Transduction

Genetic Alliance. consumer health - B-Cell Lymphomas.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20017807.001).

[ISSN] 1365-3083

[Journal-full-title] Scandinavian journal of immunology

[ISO-abbreviation] Scand. J. Immunol.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / DLL4 protein, human; 0 / Dipeptides; 0 / HEY2 protein, human; 0 / Homeodomain Proteins; 0 / Intercellular Signaling Peptides and Proteins; 0 / N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester; 0 / Receptors, Notch; 0 / Repressor Proteins; 0 / Transforming Growth Factor beta; 149348-15-2 / HES1 protein, human; EC 3.4.- / Amyloid Precursor Protein Secretases

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Primary intraocular B-cell lymphoma: case report].

[Transliterated title] Linfoma intra-ocular primário de células tipo B: relato de caso.

Ocular non-Hodgkin's lymphoma is a rare condition that can involve the retina, the vitreous and the optic nerve.

It can occur alone or can be associated with lymphoma of the central nervous system and a frequent manifestation is a posterior uveitis of difficult treatment.

This kind of ocular tumor is difficult and a challenge to diagnosis.

We describe a case of non-Hodgkin's intraocular B-cell lymphoma in a 47-year-old woman who had a posterior uveitis as the first manifestation.

We emphasize the importance of a careful investigation and of the general clinical examination since this is the most common type in the eye.

We expect to call the attention to this disease that many times appears in an unspecific form with unspecific symptoms.

[MeSH-major] Eye Neoplasms / diagnosis. Lymphoma, B-Cell / diagnosis

[MeSH-minor] Female. Humans. Lymphoma, Non-Hodgkin / diagnosis. Middle Aged. Uveitis / diagnosis

MedlinePlus Health Information. consumer health - Eye Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17906772.001).

[ISSN] 0004-2749

[Journal-full-title] Arquivos brasileiros de oftalmologia

[ISO-abbreviation] Arq Bras Oftalmol

[Language] por

[Publication-type] Case Reports; English Abstract; Journal Article

[Publication-country] Brazil

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Translocation (18;22)(q21;q11) in B-cell lymphomas: a report of 4 cases and review of the literature.

Follicular lymphomas characteristically carry t(14;18)(q32;q21) which results in IGH-BCL-2 fusion.

Variant translocations that juxtapose the BCL-2 gene with the immunoglobulin kappa (2p11) and lambda (22q11) light chain genes are rare.

We report 4 cases of B-cell lymphoma/leukemia associated with t(18;22)(q21;q11).

Three cases were classified as chronic lymphocytic leukemia, and one as follicular lymphoma based on morphology and immunophenotype.

Fluorescence in situ hybridization analysis was performed on all 4 cases using a BCL-2 breakapart probe.

The BCL-2 gene was rearranged in all cases.

These cases illustrate that t(18;22)(q21;q11) is more commonly observed in chronic lymphocytic leukemia and may represent either an initial or secondary genetic event.

[MeSH-major] Chromosomes, Human, Pair 18. Chromosomes, Human, Pair 22. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Lymphoma, B-Cell / genetics

[MeSH-minor] Aged. Fatal Outcome. Female. Gene Rearrangement, B-Lymphocyte. Genes, bcl-2. Humans. Male. Middle Aged. Translocation, Genetic

Genetic Alliance. consumer health - B-Cell Lymphomas.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18656237.001).

[ISSN] 1532-8392

[Journal-full-title] Human pathology

[ISO-abbreviation] Hum. Pathol.

[Language] eng

[Publication-type] Case Reports; Journal Article; Review

[Publication-country] United States

[Number-of-references] 25

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] A complete response with rituximab in metastatic diffuse large B-cell lymphoma of the testis: case report.

Primary testicular lymphoma is an uncommon testicular tumour.

We present a case of a primary non-Hodgkin lymphoma of the testis, describing its clinical and pathological features and discussing our treatment strategy.

Light microscopy demonstrated the classic appearance of a diffuse large B-cell lymphoma.

The immunohistochemical study showed tumour cells intensively positive for CD45, Ki67 and CD20.

No evidence of extra-testicular involvement by lymphoma was found.

At 6 months, a TC-PET showed a clinical relapse in lung and abdominal lymphonodes, while clinical examination demonstrated a single, indolent and erythematous nodule in the left foot.

The histologic analysis confirmed diagnosis of CD-20 positive B-cell lymphoma.

After 3 months a complete response was observed in all sites of disease.

The patient was free from disease at 12 months follow-up.

[MeSH-major] Antibodies, Monoclonal / pharmacology. Antineoplastic Agents / pharmacology. Lymphoma, B-Cell / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Testicular Neoplasms / drug therapy

Genetic Alliance. consumer health - Large B cell diffuse lymphoma.

MedlinePlus Health Information. consumer health - Testicular Cancer.

Hazardous Substances Data Bank. RITUXIMAB .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17624254.001).

[ISSN] 0394-6320

[Journal-full-title] International journal of immunopathology and pharmacology

[ISO-abbreviation] Int J Immunopathol Pharmacol

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

[Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Clinical, laboratory, and histopathologic features of equine lymphoma.

Clinical, laboratory and tissue findings from 37 horses with lymphoma were investigated.

Tumor cell morphology was heterogeneous in 17 tumors, and 8 tumors had marked histiocytic and multinucleated giant cell infiltrates.

Extensive necrosis or focal fibrosis was present in 22 and 4 lymphomas, respectively.

Staining of tumor sections with antibodies against CD3 and CD79alpha molecules resulted in classification of T-cell (n = 26) or B-cell (n = 7) origin.

Most T-cell tumors comprised small to medium CD3(+) lymphocytes, whereas 5 of 7 B-cell tumors were infiltrated by numerous small T lymphocytes and classified as T-cell-rich B-cell lymphoma.

Fresh tumor cells from 6 horses bound antibodies reactive with equine CD4, CD5, CD8, CD21, or major histocompatibility class II molecules, confirming T-cell (n = 5) or B-cell origin (n = 1).

These findings suggest that T-cell lymphoma is more common than B-cell lymphoma in horses and that inflammation, possibly from tumor cytokine production, is frequent.

[MeSH-major] Horse Diseases / pathology. Lymphoma / veterinary

MedlinePlus Health Information. consumer health - Lymphoma.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17099148.001).

[ISSN] 0300-9858

[Journal-full-title] Veterinary pathology

[ISO-abbreviation] Vet. Pathol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Non-Hodgkin lymphoma (NHL) subtypes defined by common translocations: utility of fluorescence in situ hybridization (FISH) in a case-control study.

We used fluorescence in situ hybridization (FISH) assays to identify t(14;18) translocations in archival paraffin-embedded tumor sections from non-Hodgkin lymphoma (NHL) cases enrolled in a population-based study. t(14;18) was identified in 54% of 152 cases, including 39% of diffuse large cell lymphomas (26 of 66 cases) and 84% of follicular lymphomas (36 of 43 cases).

Eighty-seven percent of t(14;18)-positive cases and 57% of t(14;18)-negative cases expressed bcl-2.

FISH assays detected twice as many t(14;18)-positive follicular lymphomas as PCR assays.

Genetic Alliance. consumer health - Hodgkin lymphoma.

Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

COS Scholar Universe. author profiles.

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] Copyright 2009 Elsevier Ltd. All rights reserved.

[Cites] Cancer Genet Cytogenet. 2003 May;143(1):73-9 [12742158.001]

[Cites] Arch Pathol Lab Med. 2008 Aug;132(8):1355-61 [18684042.001]

[Cites] Int J Hematol. 2003 Aug;78(2):154-9 [12953811.001]

[Cites] Cancer. 2003 Dec 25;99(6):385-93 [14681948.001]

[Cites] Pathology. 2004 Feb;36(1):19-44 [14757555.001]

[Cites] Cancer Genet Cytogenet. 2004 Apr 1;150(1):22-6 [15041219.001]

[Cites] Am J Pathol. 2004 Jul;165(1):159-66 [15215171.001]

[Cites] Histopathology. 2004 Nov;45(5):501-10 [15500654.001]

[Cites] J Natl Cancer Inst. 1987 Apr;78(4):675-8 [3470542.001]

[Cites] J Natl Cancer Inst. 1987 Jun;78(6):1137-44 [3473254.001]

[Cites] Am J Public Health. 1988 May;78(5):570-1 [3354743.001]

[Cites] Cancer Res. 1990 Oct 15;50(20):6585-91 [2208120.001]

[Cites] Arch Environ Health. 1991 Mar-Apr;46(2):70-4 [2006896.001]

[Cites] Leuk Res. 1991;15(5):305-14 [2046383.001]

[Cites] Cancer Res. 1992 Oct 1;52(19 Suppl):5522s-5528s [1394167.001]

[Cites] Cancer Res. 1992 Oct 1;52(19 Suppl):5529s-5540s [1394168.001]

[Cites] Am J Ind Med. 1993 Feb;23(2):301-12 [8427258.001]

[Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]

[Cites] J Clin Oncol. 1996 Mar;14(3):963-9 [8622046.001]

[Cites] Blood Cells Mol Dis. 1998 Mar;24(1):62-72 [9616042.001]

[Cites] Cancer Sci. 2005 Feb;96(2):77-82 [15723651.001]

[Cites] Leukemia. 2005 Jun;19(6):1058-63 [15815725.001]

[Cites] Am J Surg Pathol. 2005 Aug;29(8):1067-73 [16006802.001]

[Cites] Anticancer Res. 2005 Sep-Oct;25(5):3179-82 [16101124.001]

[Cites] Am J Clin Pathol. 2005 Sep;124(3):421-9 [16191511.001]

[Cites] Eur J Haematol. 2006 Apr;76(4):284-93 [16519699.001]

[Cites] Cancer. 2006 Jun 25;108(3):198-204 [16671111.001]

[Cites] Mod Pathol. 2006 Aug;19(8):1027-33 [16680153.001]

[Cites] Blood. 2006 Aug 15;108(4):1363-9 [16621961.001]

[Cites] Hum Pathol. 2007 Feb;38(2):365-72 [17134735.001]

[Cites] Am J Epidemiol. 2007 Mar 15;165(6):652-9 [17204518.001]

[Cites] Leuk Res. 2008 May;32(5):737-42 [17964648.001]

[Cites] Cancer Causes Control. 2008 Oct;19(8):859-67 [18386141.001]

[Cites] Cancer Res. 1992 Oct 1;52(19 Suppl):5456s-5462s; discussion 5462s-5464s [1394154.001]

[Cites] Genes Chromosomes Cancer. 2000 Jan;27(1):85-94 [10564590.001]

[Cites] Arch Pathol Lab Med. 1999 Dec;123(12):1189-207 [10583924.001]

[Cites] Br J Haematol. 2001 May;113(2):383-90 [11380403.001]

[Cites] Epidemiology. 2001 Nov;12(6):701-9 [11679800.001]

[Cites] Blood. 2002 Apr 1;99(7):2285-90 [11895757.001]

[Cites] Cancer Causes Control. 2002 Mar;13(2):159-68 [11936822.001]

[Cites] Leukemia. 2003 Jan;17(1):255-9 [12529690.001]

[Cites] J Mol Diagn. 2003 Aug;5(3):168-75 [12876207.001]

(PMID = 19505720.001).

[ISSN] 1873-5835

[Journal-full-title] Leukemia research

[ISO-abbreviation] Leuk. Res.

[Language] ENG

[Grant] United States / NIEHS NIH HHS / ES / P30 ES010126; United States / NCI NIH HHS / CA / R21 CA107966-01; United States / NICHD NIH HHS / HD / R24 HD050924; United States / NCI NIH HHS / CA / R03 CA71617-01; United States / NIEHS NIH HHS / ES / P30ES10126; United States / NCI NIH HHS / CA / CA107966-01

[Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Proto-Oncogene Proteins c-bcl-2

[Other-IDs] NLM/ NIHMS157999; NLM/ PMC2815151

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] A novel Bcl-2-like inhibitor of apoptosis is encoded by the parapoxvirus ORF virus.

Apoptotic cell death forms part of the host defense against virus infection.

We tested orf virus, a member of the poxvirus family, for the ability to inhibit apoptosis and found that orf virus-infected cells were fully resistant to UV-induced changes in cell morphology, caspase activation, and DNA fragmentation.

These features are comparable to the antiapoptotic properties of the mitochondrial regulator Bcl-2.

Furthermore, bioinformatic analyses revealed sequence and secondary-structure similarities to Bcl-2 family members, including characteristic residues of all four Bcl-2 homology domains.

Consistent with this, the viral protein inhibited the UV-induced activation of the proapoptotic Bcl-2 family members Bax and Bak.

ORFV125 is the first parapoxvirus apoptosis inhibitor to be identified, and we propose that it is a new antiapoptotic member of the Bcl-2 family.

[MeSH-minor] Apoptosis. Caspases / metabolism. DNA Fragmentation / radiation effects. Enzyme Activation / genetics. Enzyme Activation / radiation effects. HeLa Cells. Humans. JNK Mitogen-Activated Protein Kinases / metabolism. Mitochondria / metabolism. Protein Structure, Secondary. Protein Structure, Tertiary. Ultraviolet Rays. bcl-2 Homologous Antagonist-Killer Protein / genetics. bcl-2 Homologous Antagonist-Killer Protein / metabolism. bcl-2-Associated X Protein / genetics. bcl-2-Associated X Protein / metabolism

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Cancer Res. 2000 May 15;60(10):2666-72 [10825139.001]

[Cites] J Virol. 2004 Jan;78(1):353-66 [14671117.001]

[Cites] J Gen Virol. 2000 Nov;81(Pt 11):2803-11 [11038395.001]

[Cites] Protein Sci. 2000 Dec;9(12):2528-34 [11206074.001]

[Cites] Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3012-7 [11248023.001]

[Cites] Mol Biol Cell. 2002 May;13(5):1615-25 [12006657.001]

[Cites] Curr Opin Microbiol. 2002 Aug;5(4):395-402 [12160859.001]

[Cites] Genes Dev. 2002 Oct 1;16(19):2465-78 [12368257.001]

[Cites] J Gen Virol. 2000 Apr;81(Pt 4):1087-97 [10725436.001]

[Cites] J Virol. 2000 Apr;74(8):3815-31 [10729156.001]

[Cites] J Exp Med. 2000 May 1;191(9):1487-98 [10790424.001]

[Cites] Biochim Biophys Acta. 2004 Mar 1;1644(2-3):83-94 [14996493.001]

[Cites] Biochim Biophys Acta. 2004 Mar 1;1644(2-3):95-105 [14996494.001]

[Cites] J Virol. 2004 Jul;78(13):7097-111 [15194786.001]

[Cites] Science. 2004 Jul 30;305(5684):626-9 [15286356.001]

[Cites] Arch Virol. 1982;71(1):43-55 [6279055.001]

[Cites] Nucleic Acids Res. 1987 Sep 11;15(17):7192 [2821498.001]

[Cites] Arch Virol. 1988;101(3-4):255-9 [3178493.001]

[Cites] J Virol. 1994 Dec;68(12):7728-37 [7966562.001]

[Cites] Nature. 1996 May 23;381(6580):335-41 [8692274.001]

[Cites] Cell. 1996 Jul 12;86(1):147-57 [8689682.001]

[Cites] Science. 1997 Feb 14;275(5302):983-6 [9020082.001]

[Cites] Oncogene. 1997 Jan 30;14(4):405-14 [9053837.001]

[Cites] Virology. 1997 Mar 3;229(1):193-200 [9123861.001]

[Cites] Biochem J. 1998 Jan 1;329 ( Pt 1):95-9 [9405280.001]

[Cites] Virology. 1998 May 10;244(2):365-96 [9601507.001]

[Cites] Virus Genes. 1998;17(2):107-15 [9857983.001]

[Cites] Trends Microbiol. 1999 Apr;7(4):160-5 [10217831.001]

[Cites] Curr Opin Cell Biol. 2004 Dec;16(6):647-52 [15530776.001]

[Cites] J Virol. 2005 Jan;79(2):1084-98 [15613337.001]

[Cites] Bioinformatics. 2005 Apr 1;21(7):951-60 [15531603.001]

[Cites] Cancer Biol Ther. 2005 Feb;4(2):139-63 [15725726.001]

[Cites] Biochem J. 2005 Jul 1;389(Pt 1):83-9 [15727562.001]

[Cites] FEBS Lett. 2005 Jul 4;579(17):3503-7 [15949801.001]

[Cites] J Virol. 2005 Nov;79(22):14031-43 [16254338.001]

[Cites] Curr Opin Cell Biol. 2005 Dec;17(6):617-25 [16243507.001]

[Cites] J Virol. 2006 Feb;80(3):1140-51 [16414991.001]

[Cites] Virus Res. 2006 Mar;116(1-2):146-58 [16274827.001]

[Cites] Cell Death Differ. 2006 Sep;13(9):1423-33 [16676004.001]

[Cites] Cell Death Differ. 2006 Oct;13(10):1651-62 [16439990.001]

[Cites] J Biol Chem. 2006 Dec 22;281(51):39728-39 [17074758.001]

[Cites] Mol Cell. 2007 Mar 23;25(6):933-42 [17386268.001]

[Cites] Oncogene. 2000 May 4;19(19):2286-95 [10822379.001]

[Cites] J Cell Biol. 2003 Jan 6;160(1):53-64 [12515824.001]

[Cites] Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2432-7 [12591950.001]

[Cites] Cell Death Differ. 2003 Jan;10 Suppl 1:S68-76 [12655348.001]

[Cites] EMBO J. 2003 Apr 1;22(7):1497-507 [12660157.001]

[Cites] Bioessays. 2003 Sep;25(9):888-96 [12938178.001]

[Cites] J Cell Biol. 2003 Sep 1;162(5):877-87 [12952938.001]

[Cites] Immunity. 2003 Sep;19(3):341-52 [14499110.001]

[Cites] Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14345-50 [14610284.001]

[Cites] J Virol. 2004 Jan;78(1):168-77 [14671098.001]

[Cites] Trends Cell Biol. 2000 Sep;10(9):369-77 [10932094.001]

(PMID = 17475653.001).

[ISSN] 0022-538X

[Journal-full-title] Journal of virology

[ISO-abbreviation] J. Virol.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Inhibitor of Apoptosis Proteins; 0 / Viral Proteins; 0 / bcl-2 Homologous Antagonist-Killer Protein; 0 / bcl-2-Associated X Protein; EC 2.7.11.24 / JNK Mitogen-Activated Protein Kinases; EC 3.4.22.- / Caspases

[Other-IDs] NLM/ PMC1933275

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab.

PURPOSE: To determine overall response (OR) and complete response (CR) rates, response duration, progression-free (PFS) and overall survival and safety with the tositumomab and iodine-131 tositumomab ((131)I tositumomab) therapeutic regimen in patients with indolent, follicular large-cell, or transformed B-cell lymphoma, progressive after rituximab.

CONCLUSION: (131)I tositumomab is effective in CD20-positive lymphoma progressive after rituximab, with a 65% OR rate and median PFS of 24.5 months for responders.

[MeSH-major] Antibodies, Monoclonal / therapeutic use. Lymphoma, B-Cell / radiotherapy. Radioimmunotherapy

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. RITUXIMAB .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15613695.001).

[ISSN] 0732-183X

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / iodine-131 anti-B1 antibody; 4F4X42SYQ6 / Rituximab

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] CD4-negative variant of CD4+/CD56+ hematodermic neoplasm: description of three cases.

BACKGROUND: CD4+/CD56+ hematodermic neoplasm (HN) (blastic natural killer (NK)-cell lymphoma) is a rare entity characterized by dense, monomorphous infiltrates of medium-sized cells with blastic appearance and a characteristic immunophenotype (positivity for CD4, CD56 and CD123).

The term 'CD4+/CD56+ hematodermic neoplasm' adopted in the World Health Organization-European Organization for Research and Treatment of Cancer classification of cutaneous lymphomas may be misleading and should probably be revised in the light of all data published in the literature.

[MeSH-major] Antigens, CD4 / metabolism. Antigens, CD56 / metabolism. Killer Cells, Natural / pathology. Lymphoma, Non-Hodgkin / pathology. Skin Neoplasms / pathology

MedlinePlus Health Information. consumer health - Skin Cancer.

COS Scholar Universe. author profiles.

Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18494823.001).

[ISSN] 1600-0560

[Journal-full-title] Journal of cutaneous pathology

[ISO-abbreviation] J. Cutan. Pathol.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Denmark

[Chemical-registry-number] 0 / Antigens, CD4; 0 / Antigens, CD56; 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] EBV-induced human CD8(+) NKT cells synergise CD4(+) NKT cells suppressing EBV-associated tumours upon induction of Th1-bias.

CD8(+) natural killer T (NKT) cells from EBV-associated tumour patients are quantitatively and functionally impaired.

EBV-induced CD8(+) NKT cells drive syngeneic T cells into a Th1-bias response to suppress EBV-associated malignancies.

IL-4-biased CD4(+) NKT cells do not affect either syngeneic T cell cytotoxicity or Th cytokine secretion.

Circulating mDC1 cells from patients with EBV-associated malignancies impair the production of IFN-gamma by CD8(+) NKT cells.

In this study, we have established a human-thymus-SCID chimaera model to further investigate the underlying mechanism of EBV-induced CD8(+) NKT cells in suppressing EBV-associated malignancies.

In the human-thymus-SCID chimera, EBV-induced CD8(+) NKT cells suppress EBV-associated malignancies in a manner dependent on the Th1-bias response and syngeneic CD3(+) T cells.

However, adoptive transfer with CD4(+) NKT cells alone inhibits T cell immunity.

Interestingly, CD4(+) NKT cells themselves secrete high levels of IL-2, enhancing the persistence of adoptively transferred CD8(+) NKT cells and T cells, thereby leading to a more pronounced T cell anti-tumour response in chimaeras co-transferred with CD4(+) and CD8(+) NKT cells.

Thus, immune reconstitution with EBV-induced CD4(+) and CD8(+) NKT cells synergistically enhances T cell tumour immunity, providing a potential prophylactic and therapeutic treatment for EBV-associated malignancies.

[MeSH-major] Antigens, CD8 / immunology. Cytotoxicity, Immunologic. Epstein-Barr Virus Infections / immunology. Herpesvirus 4, Human / immunology. Hodgkin Disease / immunology. Hodgkin Disease / therapy. Lymphoma, B-Cell / immunology. Lymphoma, B-Cell / therapy. Nasopharyngeal Neoplasms / immunology. Nasopharyngeal Neoplasms / therapy. Natural Killer T-Cells / immunology. Th1 Cells / immunology

[MeSH-minor] Adoptive Transfer. Animals. Antigens, CD4 / immunology. Cell Line, Tumor. Chimera. Humans. Interferon-gamma / metabolism. Interleukin-2 / metabolism. Interleukin-4 / immunology. Lymphocyte Activation. Mice. Mice, SCID. T-Lymphocyte Subsets / immunology. T-Lymphocyte Subsets / metabolism

MedlinePlus Health Information. consumer health - Hodgkin Disease.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[ErratumIn] Cell Mol Immunol. 2011 Jul;8(4):368

(PMID = 19887050.001).

[ISSN] 2042-0226

[Journal-full-title] Cellular & molecular immunology

[ISO-abbreviation] Cell. Mol. Immunol.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] China

[Chemical-registry-number] 0 / Antigens, CD4; 0 / Antigens, CD8; 0 / Interleukin-2; 207137-56-2 / Interleukin-4; 82115-62-6 / Interferon-gamma

[Other-IDs] NLM/ PMC4003220

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Primary uterine lymphoma: report of 2 cases and review of literature.

Primary uterine non-Hodgkin's lymphoma is a rare malignancy.

We here describe 2 patients who presented with cervical growth, stage IE, diffuse large B cell histology.

They achieved complete clinical and radiological response.

[MeSH-major] Lymphoma, Non-Hodgkin / drug therapy. Uterine Neoplasms / drug therapy

[MeSH-minor] Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Female. Humans. Middle Aged. Neoplasm Staging. Prednisone / therapeutic use. Radiotherapy Dosage. Vincristine / therapeutic use

MedlinePlus Health Information. consumer health - Uterine Cancer.

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. DOXORUBICIN .

Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

Hazardous Substances Data Bank. PREDNISONE .

Hazardous Substances Data Bank. VINCRISTINE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16813759.001).

[ISSN] 1097-6868

[Journal-full-title] American journal of obstetrics and gynecology

[ISO-abbreviation] Am. J. Obstet. Gynecol.

[Language] eng

[Publication-type] Case Reports; Journal Article; Review

[Publication-country] United States

[Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol

[Number-of-references] 30

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: I. A randomized dose escalation and feasibility study with bi- and tri-weekly regimens.

BACKGROUND: To determine the maximum tolerated dose of a bi- and tri-weekly combination chemotherapy with cyclophosphamide, doxorubicin, vincristine and prednisone plus etoposide (CHOEP) regimen without stem-cell support.

PATIENTS AND METHODS: Randomized phase I/II multicenter four-level (cyclophosphamide: 1000-1200-1400-1600 mg/m2; doxorubicin: 55-60-65-70 mg/m2; etoposide: 375-450-525-600 mg/m2) dose escalation study with CHOEP-14 and CHOEP-21 in young patients (18-60 years) with newly diagnosed aggressive non-Hodgkin's lymphoma.

MedlinePlus Health Information. consumer health - Blood Disorders.

ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

Hazardous Substances Data Bank. DOXORUBICIN .

Hazardous Substances Data Bank. ETOPOSIDE .

Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

Hazardous Substances Data Bank. PREDNISOLONE .

Hazardous Substances Data Bank. VINCRISTINE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18212092.001).

[ISSN] 1569-8041

[Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology

[ISO-abbreviation] Ann. Oncol.

[Language] ENG

[Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Primary testicular diffuse large B-cell lymphoma belongs to the nongerminal center B-cell-like subgroup: A study of 18 cases.

The most common type of primary testicular lymphoma is diffuse large B-cell type, which has the potential for aggressive clinical behavior.

Diffuse large B-cell lymphoma can be further subclassified into two major prognostic categories: germinal center B-cell-like and nongerminal center B-cell-like.

Such distinction is made possible using the immunohistochemical expression of CD10, Bcl-6 and MUM1.

The aim of this study was to stratify primary testicular lymphoma of the diffuse large B-cell type according to this scheme.

Immunohistochemical stains for CD10, Bcl-6 and MUM1 were performed on 18 cases of primary testicular lymphoma of diffuse large B-cell type.

Subclassification was carried out as previously described where CD10 and/or Bcl-6 positivity and negativity for MUM1 were considered indicative of germinal center B-cell-like type and the opposite expression as nongerminal center B-cell-like type.

Of 18 cases, 16 (89%) were found to belong to the nongerminal center B-cell-like type.

Two cases (11%) were classified as germinal center B-cell-like type; one had a CD10-positive, Bcl-6-positive and MUM1-negative profile, and the other was CD10 negative, Bcl-6 positive and MUM1 negative.

We conclude that most (89%) primary testicular lymphomas of the diffuse large B-cell type belong to the nongerminal center B-cell-like subgroup and have high proliferative activity.

[MeSH-major] Lymphoma, B-Cell / pathology. Lymphoma, Non-Hodgkin / pathology. Testicular Neoplasms / pathology

[MeSH-minor] Adult. Aged. Biomarkers, Tumor / analysis. DNA-Binding Proteins / analysis. Humans. Immunoenzyme Techniques. Interferon Regulatory Factors / analysis. Male. Middle Aged. Neoplasm Staging. Neprilysin / analysis. Prognosis. Survival Rate. Testis / chemistry. Testis / pathology

Genetic Alliance. consumer health - Large B cell diffuse lymphoma.

MedlinePlus Health Information. consumer health - Testicular Cancer.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16998463.001).

[ISSN] 0893-3952

[Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

[ISO-abbreviation] Mod. Pathol.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / BCL6 protein, human; 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Interferon Regulatory Factors; 0 / interferon regulatory factor-4; EC 3.4.24.11 / Neprilysin

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Re-re-relapse of a MALT lymphoma of the conjunctiva].

BACKGROUND: The MALT lymphoma (mucosa-associated lymphoid-like tissue lymphomas) is a rare entity and belongs to the low-grade non-Hodgkin (NHL) lymphomas.

In some cases a MALT lymphoma of the conjunctiva is misdiagnosed as chronic conjunctivitis.

Mostly a MALT lymphoma of the conjunctiva can be cured by radiation and has a good prognosis.

The medical history revealed treatment for a MALT lymphoma 4 years previously and a relapse 3 years previously.

CLINICAL COURSE: To confirm the diagnosis a biopsy was done.

The histological examination demonstrated a relapse of the MALT lymphoma.

CONCLUSION: This case shows that a relapse of the MALT lymphoma may arise although the previous tumour and its relapse were resected totally.

[MeSH-major] Conjunctival Neoplasms / diagnosis. Lymphoma, B-Cell, Marginal Zone / diagnosis. Neoplasm Recurrence, Local / diagnosis

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18712659.001).

[ISSN] 1439-3999

[Journal-full-title] Klinische Monatsblätter für Augenheilkunde

[ISO-abbreviation] Klin Monbl Augenheilkd

[Language] ger

[Publication-type] Case Reports; English Abstract; Journal Article

[Publication-country] Germany

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Despite the effectiveness of the anti-CD20 monoclonal antibody (mAb) Rituximab (C2B8) in the treatment of B-cell lymphoma, its efficacy remains variable and often modest.

Unfortunately, all the current anti-CD20 mAbs effective in CDC are relatively inactive in signaling cell death and vice versa.

TetraMcAbs, with a molecular mass only 25 kDa higher than native divalent antibodies (DiMcAb), were shown not only to be as effective in mediating CDC and antibody-dependent cellular cytotoxicity against B-lymphoma cells as DiMcAbs but also to have antiproliferative and apoptosis-inducing activity markedly superior to that of DiMcAbs.

Interestingly, whereas 2F2 and C2B8 were equally effective in inducing cell growth arrest and apoptosis, the functions of their tetravalent versions, 2F2(ScFvHL)(4)-Fc and C2B8(ScFvHL)(4)-Fc, were significantly different.

Immunotherapeutic studies further showed that 2F2(ScFvHL)(4)-Fc was far more effective in prolonging the survival of severe combined immunodeficient mice bearing systemic Daudi or Raji tumors than C2B8, 2F2, and C2B8(ScFvHL)(4)-Fc, suggesting that it might be a promising therapeutic agent for B-cell lymphoma.

[MeSH-major] Antibodies, Monoclonal / pharmacology. Antigens, CD30 / immunology. Antineoplastic Agents / pharmacology. Burkitt Lymphoma / therapy. Lymphoma, B-Cell / therapy

[MeSH-minor] Animals. Antibodies, Monoclonal, Murine-Derived. CHO Cells. Cell Line, Tumor. Cricetinae. Cricetulus. Female. Humans. Lymphoma, T-Cell / immunology. Lymphoma, T-Cell / therapy. Mice. Mice, Inbred BALB C. Mice, Inbred ICR. Mice, SCID. Rituximab. Xenograft Model Antitumor Assays

Hazardous Substances Data Bank. RITUXIMAB .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18381448.001).

[ISSN] 1538-7445

[Journal-full-title] Cancer research

[ISO-abbreviation] Cancer Res.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD30; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] B-cell lymphoma 6 and the molecular pathogenesis of diffuse large B-cell lymphoma.

PURPOSE OF REVIEW: The B-cell lymphoma 6 transcriptional repressor is the most commonly involved oncogene in B-cell lymphomas.

Sustained expression of B-cell lymphoma 6 causes malignant transformation of germinal center B cells.

Understanding the mechanism of action of B-cell lymphoma 6 is crucial for the study of how aberrant transcriptional programming leads to lymphomagenesis and development of targeted antilymphoma therapy.

RECENT FINDINGS: Identification of B-cell lymphoma 6 target genes indicates a critical role for B-cell lymphoma 6 in facilitating a state of physiological genomic instability required for germinal center B cells to undergo affinity maturation, and suggests its contribution to several additional cellular functions.

The discovery of several layers of counterregulatory mechanisms reveals how B cells can control and fine-tune the potentially lymphomagenic actions of B-cell lymphoma 6.

From the biochemical standpoint, B-cell lymphoma 6 can regulate distinct biological pathways through different cofactors.

This observation explains how the biological actions of B-cell lymphoma 6 can be physiologically controlled through separate mechanisms and affords the means for improved therapeutic targeting.

The fact that patients with B-cell lymphoma 6-dependent lymphoma can be identified on the basis of gene signatures suggests that therapeutic trials of B-cell lymphoma 6 inhibitors could be personalized to these individuals.

SUMMARY: B-cell lymphoma 6 plays a fundamental role in lymphomagenesis and is an excellent therapeutic target for development of improved antilymphoma therapeutic regimens.

Genetic Alliance. consumer health - Large B cell diffuse lymphoma.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Nature. 2004 Dec 2;432(7017):635-9 [15577913.001]

[Cites] Blood Cells Mol Dis. 2008 Jul-Aug;41(1):95-9 [18346918.001]

[Cites] Nat Med. 2004 Dec;10(12):1329-35 [15531890.001]

[Cites] J Immunol. 2005 Jan 1;174(1):205-14 [15611242.001]

[Cites] Clin Cancer Res. 2005 Jan 1;11(1):28-40 [15671525.001]

[Cites] Blood. 2005 Mar 1;105(5):1851-61 [15550490.001]

[Cites] Cancer Cell. 2005 May;7(5):445-55 [15894265.001]

[Cites] Nat Immunol. 2005 Oct;6(10):1054-60 [16142238.001]

[Cites] Mol Immunol. 2006 May;43(12):1965-71 [16423395.001]

[Cites] Oncogene. 2006 Apr 6;25(15):2223-33 [16331266.001]

[Cites] Mol Cell Biol. 2006 Sep;26(18):6880-9 [16943429.001]

[Cites] Oncogene. 2007 Jan 11;26(2):224-33 [16819511.001]

[Cites] Nature. 2000 Feb 3;403(6769):503-11 [10676951.001]

[Cites] Cancer Invest. 2000;18(4):356-65 [10808372.001]

[Cites] Genes Dev. 2000 Jul 15;14(14):1810-23 [10898795.001]

[Cites] J Exp Med. 2000 Dec 18;192(12):1841-8 [11120780.001]

[Cites] Nat Immunol. 2000 Sep;1(3):214-20 [10973278.001]

[Cites] Nature. 2001 Jul 19;412(6844):341-6 [11460166.001]

[Cites] Science. 2007 Jan 26;315(5811):528-31 [17185562.001]

[Cites] Mol Cell. 2003 Dec;12(6):1551-64 [14690607.001]

[Cites] Blood. 2004 Feb 15;103(4):1454-63 [14551142.001]

[Cites] J Immunol. 2004 Jul 15;173(2):1158-65 [15240705.001]

[Cites] Cell. 2004 Oct 1;119(1):75-86 [15454082.001]

[Cites] Proc Natl Acad Sci U S A. 2004 Sep 28;101(39):14198-203 [15375218.001]

[Cites] Blood. 1996 Jun 15;87(12):5257-68 [8652841.001]

[Cites] Science. 1997 Apr 25;276(5312):589-92 [9110977.001]

[Cites] Nat Genet. 1997 Jun;16(2):161-70 [9171827.001]

[Cites] Nature. 2007 Mar 1;446(7131):83-7 [17268470.001]

[Cites] Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3207-12 [17360630.001]

[Cites] J Exp Med. 2007 Apr 16;204(4):819-30 [17403935.001]

[Cites] Mol Cell Proteomics. 2007 May;6(5):820-34 [17296600.001]

[Cites] Nat Immunol. 2007 Jul;8(7):705-14 [17558410.001]

[Cites] Oncogene. 2007 Aug 13;26(37):5439-49 [17694085.001]

[Cites] J Pathol. 2007 Sep;213(1):106-15 [17573669.001]

[Cites] Blood. 2007 Sep 15;110(6):2067-74 [17545502.001]

[Cites] Cancer Cell. 2007 Sep;12(3):280-92 [17785208.001]

[Cites] Nat Immunol. 2007 Oct;8(10):1132-9 [17828269.001]

[Cites] Eur J Cell Biol. 2007 Oct;86(10):581-9 [17651861.001]

[Cites] Leukemia. 2007 Nov;21(11):2332-43 [17625604.001]

[Cites] Nat Genet. 2008 Jan;40(1):108-12 [18066064.001]

[Cites] Blood. 2008 Feb 1;111(3):1515-23 [17951530.001]

[Cites] J Pathol. 2008 Mar;214(4):498-507 [18189332.001]

[Cites] Nature. 2008 Feb 14;451(7180):841-5 [18273020.001]

[Cites] Mol Cell. 2008 Feb 15;29(3):384-91 [18280243.001]

[Cites] Mol Cell Biol. 2008 Apr;28(7):2175-86 [18212045.001]

[Cites] Blood. 2008 Apr 1;111(7):3701-13 [18160665.001]

[Cites] Cancer Res. 2008 May 1;68(9):3361-9 [18451163.001]

[Cites] Leuk Lymphoma. 2008 May;49(5):874-82 [18452090.001]

[Cites] Blood. 2004 Dec 15;104(13):4088-96 [15331443.001]

(PMID = 18536578.001).

[ISSN] 1531-7048

[Journal-full-title] Current opinion in hematology

[ISO-abbreviation] Curr. Opin. Hematol.

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / CA104348-05; United States / NCI NIH HHS / CA / R01 CA104348; United States / NCI NIH HHS / CA / R01 CA104348-05

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review

[Publication-country] United States

[Chemical-registry-number] 0 / Proto-Oncogene Proteins c-bcl-6

[Number-of-references] 51

[Other-IDs] NLM/ NIHMS126312; NLM/ PMC2748732